Nothing Special   »   [go: up one dir, main page]

WO2001062954A2 - Methodes et compositions utilisant la stearoyl-coa desaturase pour identifier des agents therapeutiques reduisant les triglycerides - Google Patents

Methodes et compositions utilisant la stearoyl-coa desaturase pour identifier des agents therapeutiques reduisant les triglycerides Download PDF

Info

Publication number
WO2001062954A2
WO2001062954A2 PCT/US2001/005855 US0105855W WO0162954A2 WO 2001062954 A2 WO2001062954 A2 WO 2001062954A2 US 0105855 W US0105855 W US 0105855W WO 0162954 A2 WO0162954 A2 WO 0162954A2
Authority
WO
WIPO (PCT)
Prior art keywords
scd1
activity
desaturase
polypeptide
biological activity
Prior art date
Application number
PCT/US2001/005855
Other languages
English (en)
Other versions
WO2001062954A8 (fr
WO2001062954A3 (fr
Inventor
Alison J. Brownlie
Michael R. Hayden
Alan D. Attie
James M. Ntambi
Mark P. Gray-Keller
Makoto Miyazaki
Original Assignee
Xenon Genetics, Inc.
Wisconsin Alumni Research Foundation
University Of British Columbia University Industry Liaison Office
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT01920143T priority Critical patent/ATE475718T1/de
Application filed by Xenon Genetics, Inc., Wisconsin Alumni Research Foundation, University Of British Columbia University Industry Liaison Office filed Critical Xenon Genetics, Inc.
Priority to CA2398940A priority patent/CA2398940C/fr
Priority to JP2001561763A priority patent/JP2003533978A/ja
Priority to AU2001247228A priority patent/AU2001247228B2/en
Priority to DE60142692T priority patent/DE60142692D1/de
Priority to DE01920143T priority patent/DE01920143T9/de
Priority to AU4722801A priority patent/AU4722801A/xx
Priority to EP01920143A priority patent/EP1315831B8/fr
Publication of WO2001062954A2 publication Critical patent/WO2001062954A2/fr
Publication of WO2001062954A8 publication Critical patent/WO2001062954A8/fr
Publication of WO2001062954A3 publication Critical patent/WO2001062954A3/fr
Priority to AU2007201711A priority patent/AU2007201711B2/en
Priority to AU2010200879A priority patent/AU2010200879B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)

Definitions

  • the present invention relates generally to the field of stearoyl-CoA desaturase and its involvement in various human diseases.
  • Stearoyl-CoA desaturase, and the gene encoding it, are useful for identification and development of therapeutic agents for the treatment of such diseases.
  • Acyl desaturase enzymes catalyze the formation of double bonds in fatty acids derived from either dietary sources or de novo synthesis in the liver. Mammals synthesize four desaturases of differing chain length specificity that catalyze the addition of double bonds at the ⁇ 9, ⁇ 6, ⁇ 5 and ⁇ 4 positions.
  • Stearoyl-CoA desaturases introduce a double bond in the ⁇ 9-position of saturated fatty acids.
  • the preferred substrates are palmitoyl- CoA (16:0) and stearoyl-CoA (18:0), which are converted to palmitoleoyl-CoA (16:1) and oleoyl-CoA (18:1), respectively.
  • the resulting mono-unsaturated fatty acids are substrates for incorporation into phospholipids, triglycerides, and cholesterol esters.
  • SCD1 A number of mammalian SCD genes have been cloned. For example, two genes have been cloned from rat (SCD1 , SCD2) and four SCD genes have been isolated from mouse (SCD1 , 2, 3, and 4). A single SCD gene, SCD1 , has been characterized in humans.
  • SCD genes in mice and rats adds additional complexity to determining the specific role of each of these genes in disease processes. Differences in tissue expression profiles, substrate specificity, gene regulation and enzyme stability may be important in elucidating which SCD gene plays the dominant role in each disorder. Most previous SCD studies assess SCD gene function by measuring mRNA levels or by measuring levels of monounsaturated fatty acids as an indirect measure of SCD enzyme activity. In both these cases this analysis may be misleading.
  • this invention relates to cholesterol and lipid metabolism, which in humans has been intensely studied. Since cholesterol is highly apolar, it is transported through the bloodstream in the form of lipoproteins consisting essentially of a core of apolar molecules such as cholesterol ester and triglyceride surrounded by an envelope of amphipathic lipids, primarily phospholipids. In humans, approximately 66% of cholesterol is transported on low density lipoprotein (LDL) particles, about 20% on high density lipoprotein (HDL) particles, and the remainder on very low density lipoprotein (VLDL) particles.
  • LDL low density lipoprotein
  • HDL high density lipoprotein
  • VLDL very low density lipoprotein
  • Asebia mouse (Gates, et al. (1965) Science. 148:1471-3). This mouse is a naturally occurring genetic variant mouse that has a well known defect in sebaceous glands, resulting in hair loss and scaly skin. The Asebia mouse has recently been reported to have a deletion in SCD1 resulting in the formation of an early termination site in exon 3 of the SCD1 gene. Animals homozygous for this mutation, or a distinct deletion allele which encompasses exons 1-4, do not express detectable amounts of the wild-type SCD1 mRNA transcript (November 1999. Nature Genetics. 23:268 et seq.; and PCT patent publication WO 00/09754)].
  • This invention discloses, for the first time, the role of human stearoyl- CoA desaturase-1 ("hSCDI”) in a wide range of human diseases and disorders.
  • SCD1 biological activity in humans is directly related to serum levels of triglycerides and VLDL.
  • SCD1 biological activity also affects serum levels of HDL, LDL, and/or total cholesterol, reverse cholesterol transport, and the production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and/or the like.
  • the screening assay identifies inhibitors of hSCDI which lower serum triglyceride levels and provide an important cardioprotective benefit for humans.
  • the present invention relates to vectors comprising human stearoyl-CoA desaturase (hSCDI) genes and promoter sequences and to recombinant eukaryotic cells, and cell lines, preferably mammalian cells, and most preferably human cells, and cell lines, transfected so as to comprise such vectors and/or said polynucleotides and wherein said cells express hSCDI .
  • hSCDI human stearoyl-CoA desaturase
  • Pharmaceutical compositions comprising such agents are specifically contemplated.
  • an assay is provided for identifying cSNPs (coding region single nucleotide polymorphisms) in hSCDI of an individual which are associated with human disease processes or response to medication.
  • the present invention also provides a process for diagnosing a disease or condition in a patient, commonly a human being, suspected of being afflicted therewith, or at risk of becoming afflicted therewith, comprising obtaining a tissue sample from said patient and determining the level of activity of hSCDI in the cells of said tissue sample and comparing said activity to that of an equal amount of the corresponding tissue from a patient not suspected of being afflicted with, or at risk of becoming afflicted with, said disease or condition.
  • the present invention also provides a process for diagnosing a disease or condition in a patient, commonly a human being, suspected of being afflicted therewith, or at risk of becoming afflicted therewith, comprising obtaining a tissue sample from said patient and identifying mutations in the hSCDI gene in the cells of said tissue sample and comparing said gene to that of a corresponding tissue from a patient not suspected of being afflicted with, or at risk of becoming afflicted with, said disease or condition.
  • FIG. 1 Generation of SCD1 null mice
  • A Targeting strategy for SCD1.
  • a partial map of the genomic locus surrounding the Scd1 locus is shown. Homologous recombination resulted in the replacement of exons 1-6 by neo 7 gene.
  • Gene-targeting events were verified by Southern blot analysis using EcoRI and probe A or B or by PCR analysis.
  • C Northern blot analysis.
  • D Immunoblot analysis of liver showed the absence of immunoreactive SCD in SCD1 -/- mice, whereas SCD1 protein was detected in liver tissue from both wild-type and heterozygote mice in a manner dependent on gene dosage.
  • the top two panels depict the triglyceride content of the lipoprotein fractions, the bottom two panels depict the cholesterol content of the lipoprotein fractions.
  • Ratio of monounsaturated to saturated fatty acid in mouse plasma decreases in a manner directly proportional to the level of SCD activity I. Comparison of SCD1 knock-out and asebia mice to their respective controls.
  • Figure 5 shows a linear regression analysis using a human data set.
  • Figure 10 shows an analysis of a family (NL-001), which segregated a low HDL phenotype of unknown genetic etiology and tended towards the relationships observed in Figures 5-9.
  • Figure 11 shows an analysis of family NL-0020 which segregated an ABCA1 mutation and tended towards the relationships noted in Figures 5-9.
  • Figure 13 is a plasma fatty acid analysis showing a significantly elevated 18:1/18:0 ratio in hyperiipidemic mice (HcB-19) when compared to unaffected controls of the parental strain (C3H).
  • Figure 14 Location of regulatory sequences and binding sites in homologous region of the mouse SCD1 and human SCD1 promoter and 5'- flanking regions. The top scale denotes the position relative to the transcriptional start site. Important promoter sequence elements are indicated.
  • FIG. 15 Human HepG2 cells cultured and treated with a range of doses of arachidonic acid, DHA or 10 ⁇ g/ ml cholesterol or EPA as indicated. Total mRNA was isolated and quantified.
  • HPTLC high performance TLC
  • Figure 17 shows an assay for SCD1 desaturase activity by quantifying transfer of 3 H from stearate to water.
  • the figure shows a time course of 3 H- water production at room temperature. Microsomes from wild type livers were used for this experiment. A turnover number for SCD1 activity under these conditions was estimated at 2 nmol/min/mg protein, which is about half that observed at 37°C.
  • Figure 18 shows validation that the assay monitors specifically SCD1- dependent desaturation of stearoyl-CoA.
  • Livers were collected from wild type and SCD1 knockout mice following 3 days on a high carbohydrate fat-free diet (this induces SCD1 expression in liver by about 50-fold), homogenized and a portion used for microsome purification. 3 H-water production was determined for 15 minutes at RT (room temperature) in both homogenate and microsome preparations at equivalent protein concentration, followed by quenching the reaction with acid and using charcoal to separate substrate from product. Quenching the sample with acid prior to the addition of substrate offers a blank, or control containing background radioactivity without any desaturation reaction.
  • the figure shows that desaturation activity in microsomes is greatly enriched compared to the homogenate for wild type livers, while the microsomes from the -/- SCD1 knockout animal has very little activity.
  • the "window”, or SCD1 -dependent desaturation in this assay, is a highly visible and significant 160-fold difference between wild type and SCD1 knockout microsomes.
  • Figure 19 shows inhibition of SCD1 with 3 known fatty acid inhibitors.
  • Microsomes from wild type mice were used to test the effectiveness of three known inhibitors of SCD1 : conjugated linoleic acid (CLA), 9-thia stearic acid (9-thia) and sterculic acid (SA).
  • Panel A shows that when added as the free fatty acid none were effective to suppress SCD1 activity.
  • panel B shows that if pre-conjugated to CoA (done by incubating the microsomes with CoA and ATP prior to the addition of 3H-stearoyl CoA) the three inhibitors show graded inhibition of SCDIwith sterculic acid suppressing nearly 100% of the activity for the preincubation condition.
  • This experiment establishes that SCD1 activity can be inhibited with known inhibitors but they appear to require conjugation with CoA.
  • An important use of this screening assay is to find small molecules that are potent inhibitors of SCD1 biological activity without conjugation to CoA.
  • isolated in the context of the present invention with respect to polypeptides or polynucleotides means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring).
  • a naturally-occurring polynucleotide or polypeptide present in a living organism is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the co-existing materials in the natural system, is isolated.
  • Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.
  • the polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.
  • nucleic acids and polypeptide expression products disclosed according to the present invention may be in "enriched form.”
  • enriched means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural concentration (for example), advantageously 0.01 %, by weight, preferably at least about 0.1 % by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated.
  • sequences, constructs, vectors, clones, and other materials comprising the present invention can advantageously be in enriched or isolated form.
  • polynucleotides, and recombinant or immunogenic polypeptides, disclosed in accordance with the present invention may also be in "purified” form.
  • the term “purified” does not require absolute purity; rather, it is intended as a relative definition, and can include preparations that are highly purified or preparations that are only partially purified, as those terms are understood by those of skill in the relevant art.
  • individual clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.
  • claimed polypeptide which has a purity of preferably 0.001%, or at least 0.01% or 0.1%; and even desirably 1% by weight or greater is expressly contemplated.
  • coding region refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding in vivo for the native expression product of the gene.
  • the coding region can be from a normal, mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.
  • nucleotide sequence refers to a heteropolymer of deoxyribonucleotides (for DNA) or ribonucleotides (for RNA).
  • DNA segments encoding the proteins provided by this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.
  • expression product means that polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino acid(s).
  • fragment when referring to a coding sequence, means a portion of DNA comprising less than the complete coding region whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.
  • primer means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3'OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.
  • promoter means a region of DNA involved in binding of RNA polymerase to initiate transcription, and includes all nucleotides upstream (5') of the transcription start site.
  • reference to a DNA sequence includes both single stranded and double stranded DNA.
  • specific sequence unless the context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded
  • the present invention further relates to a polypeptide which has the deduced amino acid sequence, as well as fragments, analogs and derivatives of such polypeptide.
  • fragment when referring to the polypeptide, means a polypeptide which retains essentially the same biological function or activity as such polypeptide.
  • an analog includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide.
  • Such fragments, derivatives and analogs must have sufficient similarity to the SCD1 polypeptide so that activity of the native polypeptide is retained.
  • the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide or a synthetic polypeptide, and is preferably a recombinant polypeptide.
  • the fragment, derivative or analog of the SCD1 polypeptide may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence.
  • a conserved or non-conserved amino acid residue preferably a conserved amino acid residue
  • substituted amino acid residue may or may not be one encoded by the genetic code
  • the present invention also relates to an isolated stearoyl-CoA desaturase encoded by the isolated polynucleotide of the invention.
  • Fragments or portions of the polypeptides of the present invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, the fragments may be employed as intermediates for producing the full-length polypeptides. Fragments or portions of the polynucleotides of the present invention may be used to synthesize full-length polynucleotides of the present invention.
  • portion when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence.
  • the oligopeptides resulting from such treatment would represent portions, segments or fragments of the starting polypeptide.
  • polynucleotides such terms refer to the products produced by treatment of said polynucleotides with any of the common endonucleases.
  • the present invention relates to the activity of human stearoyl-CoA desaturase-1 in human disease processes.
  • compounds that specifically modulate human stearoyl-CoA desaturase-1 activity or expression level are useful in the treatment of a human disorder or condition relating to serum levels of triglyceride or VLDL, and provide an important cardioprotective benefit when administered to humans.
  • Compounds that modulate hSCDI activity or expression are also useful for modulating serum levels of HDL, LDL, and/or total cholesterol, and/or reverse cholesterol transport.
  • compounds that modulate hSCDI activity or expression are also useful for modulating the production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like.
  • GenBank Accession Y13647 also called NM005063
  • SCD1 Human Stearoyl-CoA Desaturase -1
  • GenBank Accession Y13647 also NM005063
  • SCD1 including partial promoter sequences can be found on GenBank under the following accession numbers: gb
  • the present invention relates to uses of an isolated polynucleotide comprising a non-genomic polynucleotide having at least 90% identity, preferably 95% identity, most preferably at least a 98% identity to the sequence of human stearoyl-CoA reductase-1 , especially where said sequences are the same and including any of the complements of any of the foregoing.
  • hSCDI The full promoter sequence of hSCDI is SEQ ID. No. 1 and Figure 14 illustrates the functional elements conserved between the mouse and human SCD1 promoter regions.
  • the present invention relates to uses of an isolated polypeptide having at least 90% identity, preferably 95% identity, most preferably at least a 98% identity to human stearoyl-CoA reductase-1 , especially where said sequences are the same.
  • the polypeptide sequence has been previously disclosed and can be found at the following SwissProtein database accession series: ACCESSION No. O00767; PID g3023241 ; VERSION O00767 GL3023241 ; DBSOURCE: swissprot: locus
  • polypeptide sequence can be determined from the cDNA sequence references provided above.
  • a number of human diseases and disorders are the result of aberrant SCD1 biological activity and may be ameliorated by modulation of SCD1 biological activity using therapeutic agents.
  • Example 1 shows that the lipoprotein profiles of SCD1 knock-out mice demonstrate a 65% reduction in serum triglyceride and VLDL levels. These correspond with the lipoprotein profiles of Asebia mice which are also included herein.
  • the lipoprotein profiles of both the Asebia and the SCD1 knock-out mouse were not previously known but due to the targeted and specific nature of the engineered mutation, the correlation of SCD1 activity and serum triglyceride levels can be drawn with certainty. While other SCD isoforms may play a role in triglyceride levels, this data indicates that SCD1 , specifically, plays the major role in this process.
  • 148:1471-3 shows a major and significant alteration in serum lipoprotein profile including a large reduction in triglyceride and VLDL levels. In addition, these animals have a large decrease in liver content of cholesterol esters. In accordance therewith, effective inhibition of SCD1 activity would lead to a reduction in triglyceride levels, due to decreased availability of monounsaturated fatty acids.
  • Monounsaturated fatty acids are the preferred substrate for the enzyme responsible for triglyceride (TG) synthesis from fatty acids and glycerol phosphate (viz., glycerol phosphate acyl transferase (GPAT)).
  • increased esterification of cholesterol prevents the toxic accumulation of free cholesterol in liver, and the increase in the availability of cholesterol esters and triglycerides also facilitates their secretion in the form of VLDL.
  • Increased cholesterol esterification in macrophages may also enhance the formation of foam cells and thereby contribute to atherosclerotic lesion development.
  • the inhibition of SCD activity may have the added effect of reducing the level of VLDL particles in the bloodstream and inhibiting atherosclerosis.
  • inhibition of SCD1 is also advantageous in increasing the formation of HDL at peripheral tissues.
  • cellular cholesterol is predominantly in the esterified form, with low levels of free cholesterol.
  • Acyl-CoA:cholesterol acyltransferase (ACAT) is the enzyme responsible for esterifying cholesterol using monounsaturated fatty acyl-CoA's as a preferred substrate.
  • SCD generates the monounsaturated products, which are then available for cholesterol esterification by ACAT.
  • the increased flux of free cholesterol out of cells and through HDL is thought to be therapeutically beneficial because it would signify enhanced "reverse cholesterol transport" (RCT).
  • SCD1 is also useful in increasing reverse cholesterol transport (RCT) without necessarily raising the serum HDL level.
  • Serum HDL level is a surrogate marker for the process of RCT, which in fact preferably is measured by the overall flux of cholesterol from peripheral tissues to the liver.
  • the invention identifies modulators of SCD1 biological activity as effective therapeutic agents for increasing RCT.
  • RCT can be directly measured, for example, by injecting radiolabelled cholesterol ether incorporated into HDL particles directly into the blood, and measuring the clearance rate (the rate at which it is taken up into the liver of an organism).
  • the experiment compared SR-B1 mRNA expression in the liver of +/+ versus -/- SCDI mice (strains as described in the Examples below). When expressed relative to the +/+ animal on chow diet the results show the following for changes in ABCA1 and SR-B1 mRNA levels: The changes in ABC1 are not significant while those shown for SR-B1 on a chow diet are. An increase in SR-B1 expression indicates increased flux, or RCT, of cholesterol to the liver and may explain why there is no observation of elevated HDL-C in the plasma of the -/- SCD1 mouse.
  • Increased RCT is further confirmed by the finding that -/- animals on high cholesterol diet have a gall bladder roughly 10-times the size of the +/+ animals and which are engorged with bile. These observations are consistent with increased removal of cholesterol by the liver, hence increased RCT. Further, the apparently identical increase in SR-B1 in +/+ and -/- mice may not reflect an identical phenotype or biological process in these animals.
  • Inhibition of SCD expression may also affect the fatty acid composition of membrane phospholipids, as well as triglycerides and cholesterol esters.
  • the fatty acid composition of phospholipids ultimately determines membrane fluidity, while the effects on the composition of triglycerides and cholesterol esters can affect lipoprotein metabolism and adiposity.
  • the present invention also relates to the involvement of SCD1 in other human disorders or conditions relating to serum levels of HDL, LDL, and total cholesterol as well as the role of SCD1 in other human disorders or conditions relating to the production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like.
  • the invention encompasses modulators of SCD1 that are useful for treating these disorders.
  • SCD1 transcription regulating proteins for SCD1 are identified. These proteins are targets for compounds that increase or decrease SCD1 expression in cells, thereby influencing, either positively or negatively, SCD1 biological activity of cells.
  • PPAR-gamma and SREBP are examples. Compounds which are known to act through such transcription regulators may now be identified as relevant for treating the SCD1 related diseases and disorders now identified in humans.
  • the present invention provides screening assays employing the hSCDI gene and/or protein for use in identifying therapeutic agents for use in treating a disorder or condition relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, reverse cholesterol transport, the production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like.
  • SCD1 biological activity as used herein, especially relating to screening assays, is interpreted broadly and contemplates all directly or indirectly measurable and identifiable biological activities of the SCD1 gene and protein. Relating to the purified SCD1 protein, SCD1 biological activity includes, but is not limited to, all those biological processes, interactions, binding behavior, binding-activity relationships, pKa, pD, enzyme kinetics, stability, and functional assessments of the protein.
  • SCD1 biological activity in cell fractions, reconstituted cell fractions or whole cells these activities include, but are not limited the rate at which the SCD introduces a cis-double bond in its substrates palmitoyl-CoA (16:0) and stearoyl-CoA (18:0), which are converted to palmitoleoyl-CoA (16:1) and oleoyl-CoA (18:1), respectively, and all measurable consequences of this effect, such as triglyceride, cholesterol, or other lipid synthesis, membrane composition and behavior, cell growth, development or behavior and other direct or indirect effects of SCD1 activity.
  • SCD1 biological activity includes the rate, scale or scope of transcription of genomic DNA to generate RNA; the effect of regulatory proteins on such transcription, the effect of modulators of such regulatory proteins on such transcription; plus the stability and behavior of mRNA transcripts, post-transcription processing, mRNA amounts and turnover, and all measurements of translation of the mRNA into polypeptide sequences.
  • SCD1 biological activity in organisms this includes but is not limited biological activities which are identified by their absence or deficiency in disease processes or disorders caused by aberrant SCD1 biological activity in those organisms. Broadly speaking, SCD1 biological activity can be determined by all these and other means for analyzing biological properties of proteins and genes that are known in the art.
  • the screening assays contemplated by the present invention may also employ isoforms of SCD from humans or other organisms that demonstrate similar biological activity as hSCDI so long as they succeed in identifying therapeutic agents for human diseases.
  • the functional equivalency of delta-9 desaturases from vertebrates has been recognized by those in the art. Consequently, specific embodiments of the present invention may employ one or more functionally equivalent delta-9 desaturase enzymes from another vertebrate species to identify therapeutic agents useful for humans.
  • Functionally equivalent desaturases include all of the mouse, rat, cow, pig or chicken SCDs identified above, in addition to the genes identified at the UniGene Cluster Hs.119597 SCD for Stearoyl-CoA desaturase (delta-9- desaturase).
  • LocusLink 6319; OMIM: 604031 or HomoloGene: Hs. 119597.
  • Other known delta-9 desaturases include pig: O02858 (swiss-prot); and cow: AF188710 (NCBl, [6651449, Genbank]) SELECTED MODEL ORGANISM PROTEIN SIMILARITIES
  • H. sapiens SP:O00767- 100 % / 358 aa
  • M. musculus PIR:A32115- 83 % / 357 aa
  • R. norvegicus SP:P07308- 84 % / 357 aa
  • D. melanogaster PID:g1621653- 57 % / 301 aa
  • C. elegans PID:g3881877- 52 % / 284 aa
  • S. cerevisiae PID:e243949- 36 % / 291 aa
  • screening assays may be cell based, cell extract (i.e. microsomal assays), cell free (i.e. transcriptional) assays, and assays of substantially purified protein activity.
  • assays are typically radioactivity or fluorescence based (i.e. fluorescence polarization or fluorescence resonance energy transfer or FRET), or they may measure cell behavior (viability, growth, activity, shape, membrane fluidity, temperature sensitivity etc).
  • FRET fluorescence polarization or fluorescence resonance energy transfer or FRET
  • screening may employ multicellular organisms, including genetically modified organisms such as knock-out or knock-in mice, or naturally occurring genetic variants. Screening assays may be manual or low throughput assays, or they may be high throughput screens which are mechanically/robotically enhanced.
  • the aforementioned processes afford the basis for screening processes, including high throughput screening processes, for determining the efficacy of potential therapeutic and diagnostic drugs for treating the diseases described herein, preferably diseases in which increased or decreased activity or expression of stearoyl-CoA desaturase (hSCDI of the invention) plays a key role in mediating such disease.
  • diseases described herein preferably diseases in which increased or decreased activity or expression of stearoyl-CoA desaturase (hSCDI of the invention) plays a key role in mediating such disease.
  • this invention relates to a method for identifying, such as from a library of test compounds, a therapeutic agent which is useful in humans for the treatment of a disorder or condition relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, comprising a) providing a screening assay having SCD1 biological activity; b) contacting said screening assay with a test compound; and c) subsequently measuring said biological activity; wherein a test compound which modulates said biological activity is said therapeutic agent, or an analog thereof.
  • the present invention relates to a process for identifying, from a library of test compounds, a therapeutic agent which is useful in humans for the treatment of a disorder or condition relating to serum levels of triglyceride or very low density lipoprotein (VLDL) comprising a) providing a screening assay having stearoyl-Coenzyme A desaturase type 1 (SCD1 ) biological activity as a component thereof; b) contacting said SCD1 activity with a test compound; c) administering to a human a compound found to modulate said activity in (b); and (d) detecting a change in serum level of triglyceride or VLDL in said human following said administering; thereby identifying an agent useful in the treatment of a disorder or condition relating to serum levels of triglyceride or very low density lipoprotein (VLDL) .
  • VLDL very low density lipoprotein
  • said agent is an antagonist or inhibitor of SCD1 biological activity. In another specific embodiment thereof, said agent is an agonist of SCD1 biological activity. In another embodiment, where said modulator is an inhibitor, said inhibitor does not substantially inhibit the biological activity in a human of a delta-5 desaturase, deIta-6 desaturase or fatty acid synthetase
  • the assay process further comprises the step of assaying said therapeutic agent to further select compounds which do not substantially inhibit in a human the activity of delta-5 desaturase, delta-6 desaturase or fatty acid synthetase.
  • the present invention also encompasses a process wherein said SCD1 biological activity is measured by an assay selected from among: a) SCD1 polypeptide binding affinity; b) SCD1 desaturase activity in microsomes; c) SCD1 desaturase activity in a whole cell assay d) quantification of SCD1 gene expression level; and e) quantification of SCD1 protein level.
  • an assay selected from among: a) SCD1 polypeptide binding affinity; b) SCD1 desaturase activity in microsomes; c) SCD1 desaturase activity in a whole cell assay d) quantification of SCD1 gene expression level; and e) quantification of SCD1 protein level.
  • Such an assay may employ a recombinant cell as disclosed herein.
  • the present invention also relates to a process wherein the identified compound is further selected from among those compounds that do not substantially inhibit in humans the biological activity of delta-5 desaturase, delta-6 desaturase or fatty acid synthetase.
  • the present invention contemplates employing SCD1 nucleic acid as disclosed herein and/or SCD1 polypeptide as disclosed herein for use in identifying compounds useful for treatment of a disorder or condition relating to serum levels of triglyceride or VLDL.
  • the assays disclosed herein essentially require the measurement, directly or indirectly, of an SCD1 biological activity.
  • Those skilled in the art can develop such assays based on well known models, and many potential assays exist.
  • methods that can be used to quantitatively measure SCD activity include for example, measuring thin layer chromatographs of SCD reaction products over time. This method and other methods suitable for measuring SCD activity are well known (Henderson Henderson RJ, et al. 1992. Lipid Analysis: A Practical Approach. Hamilton S. Eds.
  • the invention employs a microsomal assay having a measurable SCD1 biological activity.
  • a suitable assay may be taken by modifying and scaling up the rat liver microsomal assay essentially as described by Shimomura et al. (Shimomura, I., Shimano, H., Korn, B. S., Bashmakov, Y., and Horton, J. D. (1998). Tissues are homogenized in 10 vol. of buffer A (0.1 M potassium buffer, pH 7.4). The microsomal membrane fractions (100,000 X g pellet) are isolated by sequential centrifugation.
  • Reactions are performed at 37 °C for 5min with 100 ⁇ g of protein homogenate and 60 ⁇ M of [1- 14 C]-stearoyI-CoA (60,000 dpm), 2mM of NADH, 0.1 M of Tris/HCI buffer (pH 7.2). After the reaction, fatty acids are extracted and then methylated with 10% acetic chloride/methanol. Saturated fatty acid and monounsaturated fatty acid methyl esters are separated by 10 % AgNO 3 - impregnated TLC using hexane/diethyl ether (9:1) as developing solution.
  • the plates are sprayed with 0.2 % 2', 7'-dichlorofluorescein in 95% ethanol and the lipids are identified under UV light.
  • the fractions are scraped off the plate, and the radioactivity is measured using a liquid scintillation counter.
  • Specific embodiments of such SCD1 biological activity assay take advantage of the fact that the SCD reaction produces, in addition to the monounsaturated fatty acyl-CoA product, H 2 0. If 3 H is introduced into the C-9 and C-10 positions of the fatty-acyl-CoA substrate, then some of the radioactive protons from this reaction will end up in water. Thus, the measurement of the activity would involve the measurement of radioactive water.
  • substrates such as charcoal, hydrophobic beads, or just plain old-fashioned solvents in acid pH.
  • screening assays measure SCD1 biological activity indirectly.
  • Standard high-throughput screening assays centre on ligand-receptor assays. These may be fluorescence based or luminescence based or radiolabel detection.
  • Enzyme immunoassays can be run on a wide variety of formats for identifying compounds that interact with SCD1 proteins. These assays may employ prompt fluorescence or time- resolved fluorescence immunoassays which are well known.
  • P 32 labeled ATP is typically used for protein kinase assays.
  • Phosphorylated products may be separated for counting by a variety of methods.
  • Scintillation proximity assay technology is an enhanced method of radiolabel assay. All these types of assays are particularly appropriate for assays of compounds that interact with purified or semi-purified SCD1 protein.
  • the assay makes use of 3H-stearoyl CoA
  • charcoal is very efficient (>98%) at removing the unused portion of the stearoyl-CoA but has the disadvantage of being messy and under some conditions difficult to pipette. It may not be necessary to use charcoal if the stearoyl-CoA complex sufficiently aggregates when acidified and spun under moderate g-force. This can be tested by measuring the signal/noise ratio with and without charcoal following a desaturation reaction. There are also other reagents that would efficiently sediment stearoyl-CoA to separate it from the 3H-water product.
  • the assay can be done in a small volume appropriate for high throughput screening.
  • a preferred embodiment would employ a microcentrifuge satisfactory for spinning 96 well plates.
  • the following assays are also suitable for measuring SCD1 biological activity in the presence of potential therapeutic agents. These assays are also valuable as secondary screens to further select SCD1 specific modulators, inhibitors or agonists from a library of potential therapeutic agents.
  • Cellular based desaturation assays can also be used. By tracking the conversion of stearate to oleate in cells (3T3L1 adipocytes are known to have high SCD1 expression and readily take up stearate when complexed to BSA) we can evaluate compounds found to be inhibitory in the primary screen for additional qualities or characteristics such as whether they are cell permeable, lethal to cells, and/or competent to inhibit SCD1 activity in cells.
  • This cellular based assay may employ a recombinant cell line containing a delta-9 desaturase, preferably hSCDI (human SCD1).
  • the recombiant gene is optionally under control of an inducible promoter and the cell line preferably over-expresses SCD1 protein.
  • rat and mouse SCD 2 is expressed in brain.
  • a microsome preparation is made from the brain as previously done for SCD1 from liver.
  • the object may be to find compounds that would be specific to SCD1. This screen would compare the inhibitory effect of the compound for SCD1 versus SCD2.
  • SCD1 assay Although unlikely, it is possible that a compound "hit" in the SCD1 assay may result from stimulation of an enzyme present in the microsome preparation that competitively utilizes stearoyl-CoA at the expense of that available for SCD1 -dependent desaturation. This would mistakenly be interpreted as SCD1 inhibition.
  • One possibility to examine this problem would be incorporation into phospholipids of the unsaturated lipid (stearate). By determining effects of the compounds on stimulation of stearate incorporation into lipids researchers are able to evaluate this possibility.
  • Cell based assays may be preferred, for they leave the SCD1 gene in its native format. Particularly promising for SCD1 analysis in these types of assays are fluorescence polarization assays.
  • the extent to which light remains polarized depends on the degree to which the tag has rotated in the time interval between excitation and emission. Since the measurement is sensitive to the tumbling rate of molecules, it can be used to measure changes in membrane fluidity characteristics that are induced by SCD1 activity - namely the delta-9 desaturation activity of the cell.
  • An alternate assay for SCD1 involves a FRET assay. FRET assays measure fluorescence resonance energy transfer which occurs between a fluorescent molecule donor and an acceptor, or quencher. Such an assay may be suitable to measure changes in membrane fluidity or temperature sensitivity characteristics induced by SCD1 biological activity.
  • the screening assays of the invention may be conducted using high throughput robotic systems.
  • preferred assays may include chip devices developed by, among others, Caliper, Inc., ACLARA BioSciences, Cellomics, Inc., Aurora Biosciences Inc., and others.
  • SCD1 biological activity can also be measured through a cholesterol efflux assay that measures the ability of cells to transfer cholesterol to an extracellular acceptor molecule and is dependent on ABCA1 function.
  • a standard cholesterol efflux assay is set out in Marcil et al., Arterioscler. Thromb. Vase. Biol. 19:159-169, 1999, incorporated by reference herein for all purposes.
  • Preferred assays are readily adapted to the format used for drug screening, which may consist of a multi-well (e.g., 96-well, 384 well or 1536 well or greater) format. Modification of the assay to optimize it for drug screening would include scaling down and streamlining the procedure, modifying the labeling method, altering the incubation time, and changing the method of calculating SCD1 biological activity etc. In all these cases, the . _ . _,, _ ,
  • Another preferred cell based assay is a cell viability assay for the isolation of SCD1 inhibitors. Overexpression of SCD decreases cell viability. This phenotype can be exploited to identify inhibitory compounds. This cytotoxicity may be due to alteration of the fatty acid composition of the plasma membrane.
  • the human SCD1 cDNA would be placed under the control of an inducible promoter, such as the Tet- On Tet-Off inducible gene expression system (Clontech). This system involves making a double stable cell line. The first transfection introduces a regulator plasmid and the second would introduce the inducible SCD expression construct.
  • chromosomal integration of both constructs into the host genome would be favored by placing the transfected cells under selective pressure in the presence of the appropriate antibiotic.
  • SCD1 expression would be induced using the tetracycline or a tetracycline derivative (eg. Doxycycline).
  • the cells Once SCD1 expression had been induced, the cells would be exposed to a library of chemical compounds for HTS of potential inhibitors. After a defined time period, cell viability would then be measured by means of a fluorescent dye or other approach (e.g. turbidity of the tissue culture media). Those cells exposed to compounds that act to inhibit SCD1 activity would show increased viability, above background survival. Thus, such an assay would be a positive selection for inhibitors of SCD1 activity based on inducible SCD1 expression and measurement of cell viability.
  • the desaturase system has three major proteins: cytochrome bs, NADH (P)- cytochrome b 5 reductase, and terminal cyanide-sensitive desaturase.
  • Terminal cyanide-sensitive desaturase is the product of the SCD gene.
  • SCD activity depends upon the formation of a stable complex between the three aforementioned components. Thus, any agent that interferes with the formation of this complex or any agent that interferes with the proper function of any of the three components of the complex would effectively inhibit SCD activity.
  • Another type of modulator of SCD1 activity involves a 33 amino acid destabilization domain located at the amino terminal end of the pre-SCD1 protein ( Mziaut et al., PNAS 2000, 97: p 8883-8888). It is possible that this domain may be cleaved from the SCD1 protein by an as yet unknown protease. This putative proteolytic activity would therefore act to increase the stability and half-life of SCD1. Inhibition of the putative protease, on the other hand, would cause a decrease in the stability and half life of SCD1. Compounds which block or modulate removal of the destabilization domain therefore will lead to reductions in SCD1 protein levels in a cell.
  • a screening assay will employ a measure of protease activity to identify modulators of SCD1 protease activity.
  • the first step is to identify the specific protease which is responsible for cleavage of SCD1.
  • This protease can then be integrated into a screening assay.
  • Classical protease assays often rely on splicing a protease cleavage site (i.e., a peptide containing the cleavable sequence pertaining to the protease in question) to a protein, which is deactivated upon cleavage. A tetracycline efflux protein may be used for this purpose.
  • a chimera containing the inserted sequence is expressed in E. coli.
  • the present invention relates to a process for determining the ability of an agent to modulate the activity of a human stearoyl-CoA desaturase, comprising the steps of:
  • Such an assay may be carried out as a cell free assay employing a cellular fractional, such as a microsomal fraction, obtained by conventional methods of differential cellular fractionation, most commonly by ultracentrifugation methods.
  • a cellular fractional such as a microsomal fraction
  • such modulation may be an increase or decrease in the activity of the desaturase.
  • hSCDI SCD biological activity
  • SCD biological activity was measured via the surrogate marker of the ratio of 18:1 to 18:0 fatty acids in the total plasma lipid fraction. This marker indirectly measures hSCDI biological activity.
  • the present invention relates to a process for determining the ability of an agent to modulate the activity of a human stearoyl-CoA desaturase in cells expressing the human stearoyl-CoA desaturase of the invention, comprising the steps of:
  • the modulation may be an increase or decrease in activity of the desaturase and cells useful in these processes are preferably mammalian cells, most preferably human cells, and include any of the recombinant cells disclosed herein.
  • the present invention contemplates use of a SCD1 gene or protein in a recombinant cell line.
  • SCD1 recombinant cell lines may be generated using techniques known in the art, and those more specifically set out below.
  • the present invention also relates to vectors which contain polynucleotides of the present invention, and host cells which are genetically engineered with vectors of the invention, especially where such cells result in a cell line that can be used for assay of hSCDI activity, and production of SCD1 polypeptides by recombinant techniques.
  • Host cells are preferably eukaryotic cells, preferably insect cells of Spodoptera species, most especially SF9 cells.
  • Host cells are genetically engineered (transduced or transformed or transfected) with the vectors, especially baculovirus) of this invention which may be, for example, a cloning vector or an expression vector.
  • Such vectors can include plasmids, viruses and the like.
  • the engineered host cells are cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the present invention.
  • the culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • the polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques.
  • the polynucleotide may be included in any one of a variety of expression vectors for expressing a polypeptide.
  • Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies.
  • any other vector may be used as long as it is replicable and viable in the host.
  • the appropriate DNA sequence may be inserted into the vector by a variety of procedures.
  • the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art.
  • the DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis.
  • promoter for example, LTR or SV40 promoter, the E. coli. lac or trp, the phage lambda PL promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses.
  • the expression vector also contains a ribosome binding site for translation initiation and a transcription terminator.
  • the vector may also include appropriate sequences for amplifying expression.
  • the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
  • the vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein. Such transformation will be permanent and thus give rise to a cell line that can be used for further testing. Such cell lines used for testing will commonly be mammalian cells, especially human cells.
  • Spodoptera Sf9 and other insect expression systems
  • animal cells such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, and even bacterial cells, etc, all of which are capable of expressing the polynucleotides disclosed herein.
  • the selection of an appropriate host is deemed to be within the knowledge of those skilled in the art based on the teachings herein.
  • mammalian, especially human, cells are preferred.
  • the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above.
  • the constructs comprise a vector, such as a plasmid or viral vector, especially where the Baculovirus/SF9 vector/expression system is used, into which a sequence of the invention has been inserted, in a forward or reverse orientation.
  • the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available.
  • Bacterial pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, phagescript, psiX174, pBluescript SK, pBSKS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); pTRC99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.
  • Promoter regions can be selected from any desired gene using CAT
  • bacterial promoters include lacl, lacZ, T3, T7, gpt, lambda PR, P and trp.
  • Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-l. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
  • the present invention relates to host cells containing the above-described constructs.
  • the host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell.
  • Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).
  • a preferred embodiment utilizes expression from insect cells, especially SF9 cells from Spodoptera frugiperda.
  • constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.
  • the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.
  • Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.
  • Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), Wu et al, Methods in Gene Biotechnology (CRC Press, New York, NY, 1997), Recombinant Gene Expression Protocols, in Methods in Molecular Biology, Vol.
  • Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
  • recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae Trp1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence.
  • promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), ⁇ - factor, acid phosphatase, or heat shock proteins, among others.
  • PGK 3-phosphoglycerate kinase
  • the heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.
  • the heterologous sequence can encode a fusion protein including an N-terminal or C-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.
  • a Baculovirus-based expression system is a preferred and convenient method of forming the recombinants disclosed herein.
  • Baculoviruses represent a large family of DNA viruses that infect mostly insects.
  • the prototype is the nuclear polyhedrosis virus (AcMNPV) from Autographa califomica, which infects a number of lepidopteran species.
  • AcMNPV nuclear polyhedrosis virus
  • One advantage of the baculovirus system is that recombinant baculoviruses can be produced in vivo.
  • BacPAK6 a recombinant AcMNPV derivative
  • the present invention further relates to vectors comprising a polynucleotide of the invention and to recombinant eukaryotic cells expressing the stearoyl-CoA desaturase of the present invention, preferably wherein said cell is a mammalian cell, most preferably a human cell.
  • the present invention further relates to processes for using the polynucleotides, enzymes, and cells disclosed herein in a process for determining the ability of an agent to modulate the expression of said human stearoyl-CoA desaturase in cells expressing said human stearoyl-CoA desaturase of the invention, comprising the steps of:
  • the screening assay may employ a vector construct comprising the hSCDI promoter sequence of SEQ ID. No. 3 operably linked to a reporter gene.
  • a vector construct comprising the hSCDI promoter sequence of SEQ ID. No. 3 operably linked to a reporter gene.
  • Such a vector can be used to study the effect of potential transcription regulatory proteins, and the effect of compounds that modulate the effect of those regulatory proteins, on the transcription of SCD1.
  • An example of this type of vector is the pSCD-500 plasmid described in the examples below. Reporter gene constructs such as this are commonly used to indicate whether a test compound has succeeded in activating the transcription of genes under the control of a particular promoter.
  • the present invention contemplates a process wherein said modulation is an increase or decrease in said expression level and where said cell may be a mammalian cell, especially a human cell, including any of the recombinant cells disclosed herein.
  • the expression level is determined by determining the level of messenger RNA produced after contact of said cell with said agent.
  • Factors that may modulate gene expression include transcription factors such as, but not limited to, retinoid X receptors (RXRs), peroxisomal ,,, _
  • PPAR proliferation-activated receptor
  • SREBP-1 and SREBP-2 the steroid response element binding proteins
  • REV-ERB ⁇ the steroid response element binding proteins
  • ADD-1 the steroid response element binding proteins
  • EBP ⁇ the steroid response element binding proteins
  • CREB binding protein P300, HNF 4, RAR, LXR, and ROR ⁇
  • NF-Y the proliferation-activated receptor
  • C/EBPalpha PUFA-RE and related proteins and transcription regulators.
  • Screening assays designed to assess the capacity of test compounds to modulate the ability of these transcription factors to transcribe SCD1 are also contemplated by this invention.
  • Physiological benefits of an increase or decrease in the activity or expression of hSCDI include, but are not limited to, decreased plasma triglycerides and/or increased plasma HDL leading to cardioprotective benefit, therapeutic benefit in Type II diabetes, weight loss, improved gland secretions, and decreased chance of malignancy.
  • Physiological benefits of an increase or decrease in the activity or expression of hSCDI include, but are not limited to, decreased plasma triglycerides and/or increased plasma HDL leading to cardioprotective benefit, therapeutic benefit in Type II diabetes, weight loss, improved gland secretions, and decreased chance of malignancy.
  • variations in hSCDI gene expression, function, stability, catalytic activity and other characteristics may be due to allelic variations in the polynucleotide sequences encoding such enzymes.
  • the processes disclosed according to the present invention may likewise be used to determine such genomic effects on expression of hSCD Using the processes of the present invention, such variations may be determined at the level of DNA polymorphism within the hSCDI gene and/or promoter sequences. Such effects lead to the elucidation of associations between such polymorphisms and predisposition to cancer, neurological disease, skin disease, obesity, diabetes, immune function and lipid metabolism through both population and family-based genetic analysis.
  • hSCDI human health
  • models include genetically modified multicellular animals, such as knock-out or knock-in mice (as detailed in the examples below).
  • the present invention relates to a process for identifying a SCD1 -modulating agent, comprising: a) contacting under physiological conditions a chemical agent and a molecule having or inducing SCD1 activity; b) detecting a change in the activity of said molecule having or inducing SCD1 activity following said contacting; thereby identifying an SCD1 modulating agent.
  • said molecule having or inducing SCD1 activity is a polypeptide having such activity, or a polynucleotide encoding a polypeptide having such activity, or a polypeptide modulating the activity of a polynucleotide encoding a polypeptide having such activity.
  • said change in activity is an increase in activity or is a decrease in activity.
  • said contacting may be accomplished in vivo.
  • said contacting in step (a) is accomplished by administering said chemical agent to an animal afflicted with a triglyceride (TG)- or very low density lipoprotein (VLDL)-related disorder and subsequently detecting a change in plasma triglyceride level in said animal thereby identifying a therapeutic agent useful in treating a triglyceride (TG)- or very low density lipoprotein (VLDL)-related disorder.
  • the animal may be a human, such as a human patient afflicted with such a disorder and in need of treatment of said disorder.
  • SCD1 activity in said animal is a decrease in activity, preferably wherein said SCD1 modulating agent does not substantially inhibit the biological activity of a delta-5 desaturase, delta-6 desaturase or fatty acid synthetase.
  • the detected change in SCD1 activity is detected by detecting a change in any, some or all of the following: a) SCD1 polypeptide binding affinity; b) SCD1 desaturase activity in microsomes; c) SCD1 desaturase activity in a whole cell; d) SCD1 gene expression; or e) SCD1 protein level.
  • the present invention is also directed to a recombinant cell line comprising a recombinant SCD1 protein as disclosed herein.
  • the whole cell of (c) above is derived from such a cell line, preferably wherein said SCD1 modulating agent does not substantially inhibit in humans the biological activity of delta-5 desaturase, delta-6 desaturase or fatty acid synthetase.
  • a recombinant cell line of the invention may also comprise the SCD1 promoter nucleic acid sequence of SEQ ID No. 1 operably linked to a reporter gene construct.
  • the whole cell of (c) above is derived from a recombinant cell of such a cell line.
  • the present invention is also directed to an isolated stearoyl-CoA desaturase encoded by the polynucleotide sequence comprising SEQ ID No. [SCD1 cDNA] as well as a reporter gene construct comprising the SCD1 promoter nucleic acid sequence of SEQ ID No. 1 operably linked to a reporter gene, advantageously including usable vectors comprising such the nucleic acids and constructs thereof.
  • the present invention also contemplates an isolated polypeptide having stearoyl-CoA reductase activity and a process as disclosed herein that successfully identifies a chemical agent that binds to or interacts with such a polypeptide, which process comprises: a) contacting such a polypeptide, or a cell expressing such polypeptide, with a chemical agent; and b) detecting binding or interaction of the chemical agent with said polypeptide.
  • the binding of the chemical agent to the polypeptide is detected by a method selected from the group consisting of: a) direct detection of chemical agent/polypeptide binding; b) detection of binding by competition binding assay; and c) detection of binding by assay for SCD1 biological activity.
  • modulation of the activity of such polypeptide is detected by a process comprising contacting the polypeptide or a cell expressing the polypeptide with a compound that binds to the polypeptide in sufficient amount to modulate the activity of the polypeptide.
  • the molecule having or inducing SCD1 activity is selected from the group consisting of an SCD1 nucleic acid and/or SCD1 polypeptide as disclosed herein.
  • the present invention also relates to a process for treating an animal, especially a human, such as a human patient, afflicted with a disease or condition relating to serum levels of triglyceride or VLDL comprising inhibiting SCD1 activity in said human.
  • said inhibition of SCD1 activity is not accompanied by substantial inhibition of activity of delta-5 desaturase, delta-6 desaturase or fatty acid synthetase.
  • the present invention relates to a process for treating a human patient afflicted with a disorder or condition relating to serum levels of triglyceride or VLDL comprising administering to said patient a therapeutically effective amount of an agent whose therapeutic activity was first identified by the process of the invention.
  • the present invention also relates to a modulator of SCD1 activity and which is useful in humans for treatment of a disorder or condition relating to serum levels of triglyceride or VLDL wherein said activity was first identified by its ability to modulate SCD1 activity, especially where such modulation was first detected using a process as disclosed herein according to the present invention.
  • such modulating agent does not substantially inhibit fatty acid synthetase, delta-5 desaturase or delta-6 desaturase of humans.
  • the present invention also relates to a process for identifying a vertebrate delta-9 stearoyl-CoA desaturase-modulating agent, comprising:
  • the contacting in step (a) is accomplished by administering said chemical agent to an animal afflicted with a disorder or condition related to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, reverse cholesterol transport or production or secretion of mucous membranes, monounsaturated fatty acids, wax esters, and like parameters, detecting a change in the activity of said molecule having or inducing vertebrate delta-9 stearoyl-CoA desaturase activity following said contacting and thereby identifying a therapeutic agent useful in treating a triglyceride, VLDL, HDL, LDL, total cholesterol, reverse cholesterol transport or production or secretion of mucous membranes, monounsaturated fatty acids, wax esters, and like disease-related disorder.
  • the present invention further relates to a process for treating a human patient afflicted with a disease or condition relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, reverse cholesterol transport or production or secretion of mucous membranes, monounsaturated fatty acids, wax esters, and like parameters, comprising administering to said human patient a therapeutically effective amount of an agent for which such therapeutic activity was identified by a process as disclosed herein according to the invention.
  • the modulating agent does not substantially inhibit fatty acid synthetase, delta-5 desaturase or delta-6 desaturase of humans.
  • the present invention also relates to therapeutic and/or diagnostic agents, regardless of molecular size or weight, effective in treating and/or diagnosing and/or preventing any of the diseases disclosed herein, preferably where such agents have the ability to modulate activity and/or expression of the hSCDI disclosed herein, and most preferably where said agents have been determined to have such activity through at least one of the screening assays disclosed according to the present invention.
  • Test compounds are generally compiled into libraries of such compounds, and a key object of the screening assays of the invention is to select which compounds are relevant from libraries having hundreds of thousands, or millions of compounds having unknown therapeutic efficacy.
  • Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds.
  • Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, NH) and Aldrich Chemical (Milwaukee, WI).
  • libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceangraphics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA).
  • natural and synthetically produced libraries are produced, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods.
  • any library or compound is readily modified using standard chemical, physical, or biochemical methods.
  • the present invention relates to agents capable of modulating the activity and/or expression of human stearoyl-CoA desaturase 1 (hSCDI ) as disclosed herein, especially where said modulating ability was first determined using an assay of comprising hSCDIor a gene encoding hSCDI , or an assay which measures hSCDI activity.
  • hSCDI human stearoyl-CoA desaturase 1
  • the term "capable of modulating” refers to the characteristic of such an agent whereby said agent has the effect of changing the overall biological activity of hSCDI , either by increasing or decreasing said activity, under suitable conditions of temperature, pressure, pH and the like so as to facilitate such modulation to a point where it can be detected either qualitatively or quantitatively and wherein such modulation may occur in either an in vitro or in vivo environment.
  • the term “modulation” is used herein to mean a change in activity, more specifically either an increase or decrease in such activity
  • the term “activity” is not to be limited to specific enzymatic activity alone (for example, as measured in units per milligram or some other suitable unit of specific activity) but includes other direct and indirect effects of the protein, including increases in enzyme activity due not to changes in specific enzyme activity but due to changes (i.e., modulation) of expression of polynucleotides encoding and expressing said hSCDI enzyme.
  • Human SCD1 activity may also be influenced by agents which bind specifically to substrates of hSCDI .
  • modulation means a change in hSCDI activity regardless of the molecular genetic level of said modulation, be it an effect on the enzyme per se or an effect on the genes encoding the enzyme or on the RNA, especially mRNA, involved in expression of the genes encoding said enzyme.
  • modulation by such agents can occur at the level of DNA, RNA or enzyme protein and can be determined either in vivo or ex vivo.
  • said assay is any of the assays disclosed herein according to the invention.
  • the agent(s) contemplated by the present disclosure includes agents of any size or chemical character, either large or small molecules, including proteins, such as antibodies, nucleic acids, either RNA or DNA, and small chemical structures, such as small organic molecules.
  • the present invention contemplates agents wherein said agent is useful in treating, preventing and/or diagnosing a disease or condition which is identified as being SCD1 related according to this invention.
  • the disease or condition includes, but is not limited to, serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, reverse cholesterol transport or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, cholesterol disorders, lipidemias, cardiovascular disease, diabetes, obesity, baldness, skin diseases, cancer and multiple sclerosis, especially where the disease is a cardiovascular disease or a skin disease or where the condition is baldness.
  • such agents will increase HDL levels in a patient and/or decrease triglyceride levels in a patient. Either or both effects are directly associated with reduced risk of cardiovascular disease and coronary artery disease.
  • Some of the known modulators of SCD1 activity include conjugated linoleic acid especially trans-10, cis-12 isomer, and thiazoladinedione compounds such as troglitazone.
  • inhibitor classes include those inhibitors that effectively inhibit SCD1 expression, such as thiazoladinedione compounds and polyunsaturated fatty acids.
  • a second class includes those inhibitors that effectively inhibit SCD1 enzymatic activity, such as thia-fatty acids, cyclopropenoid fatty acids, and certain conjugated linoleic acid isomers.
  • the third class of inhibitors includes those agents that are capable of interfering with the proteins essential to the desaturase system, such as those agents that interfere with cytochrome b 5 , NADH (P)-cytochrome b 5 reductase, and terminal cyanide-sensitive desaturase.
  • any agent capable of disrupting the transcription of the SCD1 gene could be utilized.
  • SCD1 is regulated by several known transcription factors (e.g. PPAR- ⁇ , SREBP)
  • any agent that affects the activity of such transcription factors can be used to alter the expression of the SCD1 gene.
  • One group of such agents includes thiazoladine compounds which are known to activate PPAR- ⁇ and inhibit SCD1 transcription. These compounds include Pioglitazone, Ciglitazone, Englitazone, Troglitazone, and BRL49653.
  • Other inhibitory agents may include polyunsaturated fatty acids, such as linoleic acid, arachidonic acid and dodecahexaenoic acid, which also inhibit SCD1 transcription.
  • any agent capable of disrupting the activity of the SCD1 protein could be utilized.
  • certain conjugated linoleic acid isomers are effective inhibitors of SCD1 activity.
  • Cis-12, trans-10 conjugated linoleic acid is known to effectively inhibit SCD enzyme activity and reduce the abundance of SCD1 mRNA while Cis-9, trans-11 conjugated linoleic acid does not.
  • Cyclopropenoid fatty acids such as those found in stercula and cotton seeds, are also known to inhibit SCD activity.
  • sterculic acid (8-(2-octyl-cyclopropenyl)octanoic acid) and Malvalic acid (7-(2-octyl-cyclopropenyl)heptanoic acid) are C18 and C16 derivatives of sterculoyl- and malvaloyl fatty acids, respectively, having cyclopropene rings at their ⁇ 9 position. These agents inhibit SCD activity by inhibiting ⁇ 9 desaturation.
  • Other agents include thia-fatty acids, such as 9-thiastearic acid (also called 8-nonylthiooctanoic acid) and other fatty acids with a sulfoxy moiety.
  • the known modulators of delta-9 desaturase activity are either not know to be useful for treating the diseases and disorders linked to SCD1 biological activity as claimed in this invention, or else they are otherwise unsatisfactory therapeutic agents.
  • the thia-fatty acids, conjugated linoleic acids and cyclopropene fatty acids (malvalic acid and sterculic acid) are neither useful at reasonable physiological doses, nor are they specific inhibitors of SCD1 biological activity, rather they demonstrate cross inhibition of other desaturases, in particular the delta-5 and delta-6 desaturases by the cyclopropene fatty acids. These compounds may be useful for establishing control or test modulators of the screening assays of the invention, but are not subject to the claims of this invention.
  • Preferred SCD1 modulators of the invention have no significant or substantial impact on unrelated classes of proteins.
  • assays specific for the other proteins, such as delta- 5 and delta-6 activity will also have to be tested to ensure that the identified compounds of the invention do not demonstrate significant or substantial cross inhibition.
  • the known non-specific inhibitors of SCD1 can be useful in rational design of a therapeutic agent suitable for inhibition of SCD1 . All three inhibitors have various substitutions between carbons #9 and #10; additionally they require conjugation to Co-A to be effective; and are probably situated in a relatively hydrophobic active site. This information combined with the known X-ray co-ordinates for the active site for plant (soluble) SCD can assist the "in silico" process of rational drug design for therapeutically acceptable inhibitors specific for SCD1 .
  • This invention also provides an antibody which specifically binds to human SCD1 having the amino acid sequence shown in the SwissProt accession numbers listed above, and which thereby inhibits the activity of SCD1.
  • the instant antibody can be a polyclonal antibody, a monoclonal antibody, or an SCD-binding fragment thereof.
  • the antibody is isolated, ie.e., an antibody free of any other antibodies. Methods of making and isolating antibodies are well known in the art (Harlow, et al. 1988. Antibodies: A Laboratory Manual; Cold Spring Harbor, NY, Cold Spring Harbor Laboratory).
  • This invention also provides an antisense oligonucleotide which specifically binds to human SCD1 mRNA, and which thereby reduces the level of SCD1 gene transcription.
  • Methods of making and using antisense molecules against known target genes are known in the art (Agarwal, S. (1996) Antisense Therapeutics. Totowa, NJ, Humana Press, Inc.)
  • a screening assay such as a high throughput screening assay, will identify several or even many compounds which modulate the activity of the assay protein.
  • the compound identified by the screening assay may be further modified before it is used in humans as the therapeutic agent.
  • combinatorial chemistry is performed on the modulator, to identify possible variants that have improved absorption, biodistribution, metabolism and/or excretion, or other important therapeutic aspects.
  • the essential invariant is that the improved compounds share a particular active group or groups which are necessary for the desired modulation of the target protein.
  • Many combinatorial chemistry and medicinal chemistry techniques are well known in the art.
  • therapeutic compounds identified using an SCD1 screening assay of the invention include actual compounds so identified, and any analogs or combinatorial modifications made to a compound which is so identified which are useful for treatment of the disorders claimed herein.
  • the present invention is directed to compositions comprising the polynucleotides, polypeptides or other chemical agents, including therapeutic, prophylactic or diagnostic agents, such as small organic molecules, disclosed herein according to the present invention wherein said polynucleotides, polypeptides or other agents are suspended in a pharmacologically acceptable carrier, which carrier includes any pharmacologically acceptable diluent or excipient.
  • pharmacologically acceptable carriers include, but are not limited to, liquids such as water, saline, glycerol and ethanol, and the like, including carriers useful in forming sprays for nasal and other respiratory tract delivery or for delivery to the ophthalmic system.
  • the inhibitors utilized above may be delivered to a subject using any of the commonly used delivery systems known in the art, as appropriate for the inhibitor chosen.
  • the preferred delivery systems include intravenous injection or oral delivery, depending on the ability of the selected inhibitor to be adsorbed in the digestive tract. Any other delivery system appropriate for delivery of small molecules, such as skin patches, may also be used as appropriate.
  • the present invention further relates to a process for preventing or treating a disease or condition in a patient afflicted therewith comprising administering to said patient a therapeutically or prophylactically effective amount of a composition as disclosed herein.
  • the present invention also relates to a process for diagnosing a disease or condition in a patient, commonly a human being, suspected of being afflicted therewith, or at risk of becoming afflicted therewith, comprising obtaining a tissue sample from said patient and determining the level of activity of hSCDI in the cells of said tissue sample and comparing said activity to that of an equal amount of the corresponding tissue from a patient not suspected of being afflicted with, or at risk of becoming afflicted with, said disease or condition.
  • said disease or condition includes, but is not limited to, cholesterol disorders, lipidemias, cardiovascular disease, diabetes, obesity, baldness, skin diseases, cancer and multiple sclerosis, especially wherein said disease is a cardiovascular disease or a skin disease or said condition is baldness.
  • this invention teaches that hSCDI has pharmacogenomic significance. Variants of hSCDI including SNPs (single nucleotide polymorphisms), cSNPs (SNPs in a cDNA coding region), polymorphisms and the like may have dramatic consequences on a subject's response to administration of a prophylactic or therapeutic agent. Certain variants may be more or less responsive to certain agents. In another aspect, any or all therapeutic agents may have greater or lesser deleterious side- effects depending on the hSCDI variant present in the subject.
  • the invention discloses a process of selecting a prophylactic and/or therapeutic agent for administration to a subject in need thereof comprising,
  • the correlation may be a prophylactic and/or therapeutic effect or it may be avoidance of a deleterious side effect, or any other desired correlation.
  • an assay for identifying cSNPs (coding region small nucleotide polymorphisms) in hSCDI of an individual which are correlated with human disease processes or response to medication.
  • the inventors have identified two putative cSNPs of hSCDI to date:ln exon 1 , a C/A cSNP at nt 259, corresponding to a D/E amino acid change at position 8; and in exon 5, a C/A cSNP at nt 905, corresponding to a L/M amino acid change at position 224.
  • cSNPs may be correlated with human disease processes or response to medication of individuals who contain those cSNPs versus a control population. Those skilled in the art are able to determine which disease processes and which responses to medication are so correlated.
  • buffers, media, reagents, cells, culture conditions and the like are not intended to be limiting, but are to be read so as to include all related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another and still achieve similar, if not identical, results. Those of skill in the art will have sufficient knowledge of such systems and methodologies so as to be able, without undue experimentation, to make such substitutions as will optimally serve their purposes in using the methods and procedures disclosed herein.
  • This example identifies, for the first time, specific SCD1 biological activities in mouse by characterizing an SCD1 gene specific knock-out mouse.
  • SCD1 null mice SCD1 null mice.
  • the lipoprotein profile of SCD1 null (knock-out) mice demonstrates a striking decrease in triglyceride (i.e., VLDL) levels while maintaining approximately normal HDL and LDL levels.
  • VLDL triglyceride
  • This result confirms that a mutation in SCD1 is a causative mutation of a low triglyceride (TG) lipoprotein profile in mice, and is distinct from other SCD isoforms in the mouse in this regard. Due to the severity of this phenotype it is clear that other SCD isoforms are unlikely to affect TG levels to such a great extent.
  • Figure 1A shows the strategy used to knock out the SCD1 gene.
  • the mouse SCD1 gene includes 6 exons. The first 6 exons of the gene were replaced by a neomycin-resistant cassette by homologous recombination, resulting in the replacement of the complete coding region of the SCD1 gene (Fig. 1A).
  • the vector was electroporated into embryonic stem cells and the clones that integrated the neo cassette were selected by growth on geneticin. Targeted ES clones were injected into C57BI/6 blastocysts yielding four lines of chimeric mice that transmitted the disrupted allele through the germ-line. The mutant mice were viable and fertile and bred with predicted Mendelian distributions.
  • FIG. 1B A PCR based screen to assay successful gene targeting of the SCD1 locus is shown in Fig. 1B.
  • Fig. 1C Northern blot analysis
  • SCD1 mRNA is undetectable in liver of SCD1-/- mice and reduced by approximately 50% in SCD +/- mice.
  • SCD2 mRNA was expressed at low levels in both SCD1-/- mice and wild-type mice. Consistent with Northern blot results, Western blot analysis showed no immunoreactive SCD protein in liver from SCD -/- mice, whereas SCD1 protein was detectable in both heterozygous and wild-type liver tissue in a manner dependent on gene dosage.
  • SCD enzyme activity in liver as measured by the rate of conversion of [1- 14 C]stearoyl-CoA to [1- 14 C]oleate (Fig., 1E) was high in the wild-type mice but was undetectable in the total extracts of livers of the SCD1-/- mice.
  • Table 1 shows the fatty acid composition of several tissues in wild-type and SCD -/- mice.
  • the relative amounts of palmitoleate (16:1n-7) in liver and plasma from SCD -/- mice decreased by 55% and 47% while those of oleate (18:1 n-9) decreased by 35% and 32%, respectively.
  • the relative amount of palmitoleate in white adipose tissue and skin of SCD -/- mice were decreased by more than 70%, whereas the reduction of oleate in these tissues was less than 20% although the reduction was significant statistically.
  • Tissue total lipids from each mouse were extracted.
  • the lipids were methyl esterified and quantified by GLC as described under Experimental Procedures.
  • Figure 4 (quantified in Table 2) demonstrate that SCD1 is a major contributor to the plasma desaturation indices (ratio of plasma 18:1/18:0 or 16:1/16:0 in the total lipid fraction), as judged by plasma fatty acid analysis of both the SCD1 KO and asebia mice. In both animal models, a reduction of approximately 50% or greater is observed in the plasma desaturation indices. This demonstrates that the plasma desaturation index is highly dependent on the function of SCD1
  • Mouse genomic DNA for the targeting vector was cloned from 129/SV genomic library.
  • the targeting vector construct was generated by insertion of a 1.8-kb Xba I/Sac I fragment with 3' homology as a short arm and 4.4-kb Cla I/ Hind III fragment with 5' homology cloned adjacent to neo expression cassette.
  • the construct also contains a HSV thymidine kinase cassette 3' to the 1.8-kb homology arm, allowing positive/negative selection.
  • the targeting vector was linearized by Not I and electroporated into embryonic stem cells. Selection with geneticin and gancyclovior was performed.
  • the clones resistant to both geneticin and gancyclovior were analyzed by Southern blot after EcoRI restriction enzyme digestion and hybridized with a 0.4-kb probe located downstream of the vector sequences.
  • genomic DNA was amplified with primer A
  • PCR conditions were 35 cycles, each of 45 sec at 94 °C, 30 sec at 62 °C, and 1 min at 72 °C.
  • the targeted cells were microinjected into C57BI/6 blastocysts, and chimeric mice were crossed with C57BL/6 or 129/SvEv Taconic females, and they gave the germ-line transmission. Mice were maintained on a 12-h dark/light cycle and were fed a normal chow diet, a semi-purified diet or a diet containing 50% (% of total fatty acids) triolein, tripalmitolein or trieicosenoin.
  • the semi-purified diet was purchased from Harlan Teklad (Madison, WI) and contained: 20% vitamin free casein, 5% soybean oil, 0.3% L-cystine, 13.2% Maltodextrin, 51.7% sucrose, 5% cellulose, 3.5% mineral mix (AIN-93G-MX), 1.0% vitamin mix (AIN-93-VX), 0.3% choline bitartrate.
  • the fatty acid composition of the experimental diets was determined by gas liquid chromatography.
  • the control diet contained 11 % palmitic acid (16:0), 23% oleic acid (18:1n-9), 53% linoleic acid (18:2n-6) and 8% linolenic acid (18:3n-3).
  • the high triolein diet contained 7% 16:0, 50% 18:1n-9, 35% 18:2n-6 and 5% 18:3n-3.
  • Radioactive [ - 32 P]dCTP (3000 Ci/mmol) was obtained from Dupont Corp. (Wilmington, DE). Thin layer chromatography plates (TLC Silica Gel G60) were from Merck (Darmstadt, Germany). [1- 14 C]-stearoyl-CoA was purchased from American Radiolabeled Chemicals, Inc. (St Louis, MO). Immobilon-P transfer membranes were from Millipore (Danvers, MA). ECL Western blot detection kit was from Amersham-Pharmacia Biotech, Inc. (Piscataway, NJ). All other chemicals were purchased from Sigma (St Louis, MO).
  • Total lipids were extracted from liver and plasma according to the method of Bligh and Dyer (Bligh and Dyer, 1959), and phospholipids, wax esters, free cholesterol, triglycerides and cholesterol esters were separated by silica gel high performance TLC. Petroleum hexane/ diethyl ether/ acetic acid (80:30:1) or benzene/hexane (65:35) was used as a developing solvent (Nicolaides and Santos, 1985). Spots were visualized by 0.2% 2', T- dichlorofluorecein in 95% ethanol or by 10% cupric sulfate in 8% phosphoric acid.
  • the wax triester, cholesterol ester and triglyceride spots were scraped, 1 ml of 5% HCI-methanol added and heated at 100 °C for 1 h (Miyazaki et al., 2000).
  • the methyl esters were analyzed by gas-liquid chromatography using cholesterol heptadecanoate, triheptadecanoate and heptadecanoic acid as internal standard. Free cholesterol, cholesterol ester and triglycerides contents of eyelid and plasma were determined by enzymatic assays (Sigma St Louis, MO and Wako Chemicals, Japan).
  • Stearoyl-CoA desaturase activity was measured in liver microsomes essentially as described by Shimomura et al. (Shimomura, I., Shimano, H., Korn, B. S., Bashmakov, Y., and Horton, J. D. (1998). Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J Biol Chem 273, 35299-306. ). Tissues were homogenized in 10 vol. of buffer A (0.1 M potassium buffer, pH 7.4). The microsomal membrane fractions (100,000 X g pellet) were isolated by sequential centrifugation.
  • buffer A 0.1 M potassium buffer, pH 7.4
  • Reactions were performed at 37 °C for 5min with 100 ⁇ g of protein homogenate and 60 ⁇ M of [1- 14 C]-stearoyl-CoA (60,000 dpm), 2mM of NADH, 0.1 M of Tris/HCI buffer (pH 7.2). After the reaction, fatty acids were extracted and then methylated with 10% acetic chloride/methanol. Saturated fatty acid and monounsaturated fatty acid methyl esters were separated by 10 % AgNO ⁇ - impregnated TLC using hexane/diethyl ether (9:1) as developing solution.
  • the plates were sprayed with 0.2 % 2', 7'-dichlorofluorescein in 95% ethanol and the lipids were identified under UV light. The fractions were scraped off the plate, and the radioactivity was measured using a liquid scintillation counter. The enzyme activity was expressed as nmole min "1 mg "1 protein.
  • Tissues were fixed with neutral-buffered formalin, embedded in paraffin, sectioned and stained with hematoxylin and eosin.
  • mice Animals and D/ete-Asebia homozygous (ab J /ab J or -/-) and heterozygous (+/ab J or +/-) mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and bred at the University of Wisconsin Animal Care Facility. In this study, comparisons are made between the homozygous (-/-) and the heterozygous (+/-) mice since the latter are indistinguishable from normal mice. Mice were housed in a pathogen-free barrier facility operating a 12-h light/12-h dark cycle.
  • mice were fed ad libitum for 2 wks or 2 months, on laboratory chow diet or on a semi-purified diet containing 50% (% of total fatty acids) triolein or tripalmitolein.
  • the semi- purified diet was purchased from Harlan Teklad (Madison, WI) and contained: 18% vitamin free casein, 5% soybean oil, 33.55% corn starch, 33.55% sucrose, 5% cellulose, 0.3% -L methionine, 0.1% choline chloride, salt mix (AIN-76A) and vitamin mix (AIN-76A).
  • the fatty acid composition of the experimental diets was determined by gas liquid chromatography.
  • the control diet contained 11 % palmitic acid (16:0), 23% oleic acid (18:1 n-9), 53% linoleic acid (18:2n-6) and 8% linoleic acid (18:3n-3).
  • the high triolein diet contained 7% 16:0, 50% 18:1n-9, 35% 18:2n-6 and 5% 18:3n-3.
  • the high tripalmitolein diet contained 6% 16:0, 49% palmitoleic acid (16:1 n-7), 12% 18:1 n-9, 27% 18:2n-6 and 4% 18:3n-3.
  • Animals were anesthetized at about 10:00 a.m. by intraperitoneal injection of pentobarbital sodium (0.08 mg/g of body weight) Nembutal, Abbot, North Chicago, IL). Liver was isolated immediately, weighed, and kept in liquid nitrogen. Blood samples were obtained from the abdominal vein.
  • Mater/a/s-Radioactive - 3 2 PjdCTP (3000 Ci/mmol) was obtained from Dupont Corp. (Wilmington, DE). Thin layer chromatography plates (TLC Silica
  • Radiolabeled Chemicals, Inc. (St Louis, MO). Immobilon-P transfer membranes were from Millipore (Danvers, MA). ECL Western blot detection kit was from Amersham-Pharmacia Biotech, Inc. (Piscataway, NJ). LT-1 transfection reagent was from PanVera (Madison, WI). All other chemicals were purchased from Sigma (St Louis, MO). The antibody for rat liver microsome SCD was provided by Dr. Juris Ozols at University of Connecticut
  • pcDNA3-1 expression vector SCD1 was provided by Dr. Trabis Knight at Iowa state university.
  • Lipid yAna/ys/s-Total lipids were extracted from liver and plasma according to the method of Bligh and Dyer (Bligh, E.G., and Dyer, W.J. (1959) Can J Biochem Physiol 37, 911-917.), and phospholipids, free cholesterol, triglycerides and cholesterol esters were separated by silica gel TLC. Petroleum ether/ diethyl ether/ acetic acid (80:30:1) was used as a developing solvent. Spots were visualized by 0.2% 2', 7'-dichlorofluorecein in 95% ethanol or by 10% cupric sulfate in 8% phosphoric acid.
  • the phospholipid, cholesterol ester and triglyceride spots were scraped, 1 ml of 5% HCI- methanol added and heated at 100 0 C for 1 h.
  • the methyl esters were analyzed by gas-liquid chromatography using cholesterol heptadecanoate as internal standard (Lee, K. N., Pariza, M. W., and Ntambi, J. M. (1998) Biochem. Biophys. Res. Commun. 248, 817-821 ; Miyazaki, M., Huang, M. Z., Takemura, N., Watanabe, S., and Okuyama, H. (1998) Lipids 33, 655-61). Free cholesterol, cholesterol ester and triglycerides contents of liver and plasma were determined by enzymatic assays (Sigma St Louis, MO and Wako Chemicals, Japan).
  • Plasma Lipoprotein Analysis-Mice were fasted a minimum of 4 hours and sacrificed by CO 2 asphyxiation and/or cervical dislocation. Blood was collected aseptically by direct cardiac puncture and centrifuged (13,000 X g, 5 min, 4 0 C) to collect plasma. Lipoproteins were fractionated on a Superose 6HR 10/30 FPLC column (Pharmacia). Plasma samples were diluted 1 :1 with PBS, filtered (Cameo 3AS syringe filter, 0.22 ⁇ m) and injected onto the column that had been equilibrated with PBS containing 1mM EDTA and 0.02% NaN 3 . The equivalent of 100 ⁇ l of plasma was injected onto the column.
  • the flow rate was set constant at 0.3ml/min. 500 ⁇ l fractions were collected and used for total triglyceride measurements (Sigma). Values reported are for total triglyceride mass per fraction.
  • the identities of the lipoproteins have been confirmed by utilizing anti-ApoB immunoreactivity for LDL and Anti-Apo A1 immnunoreactivity for HDL (not shown).
  • VLDL triglyceride
  • FFA free fatty acid
  • plasma TG triglyceride
  • plasma HDL high density lipoprotein
  • Patient Sample The patient sample was chosen to maximize phenotypic diversity in terms of HDL. Within our cohort, 21 individuals displayed a high HDL phenotype (>90 th percentile for age and sex), 12 individuals displayed a low HDL phenotype of unknown etiology ( ⁇ 5 th percentile for age and sex), while six displayed a low HDL phenotype due to mutations in the ABCA1 gene. 33 individuals fall within normal HDL parameters ( ⁇ 90 th and >5 th percentile for age and sex).
  • FCHL Familial Combined Hyperlipidemia
  • multiple individuals from the same family were tested. Five of the six individuals with an ABCA1 mutation are part of the same family (NL-020). Multiple individuals were also tested from other pedigrees segregating a low HDL phenotype that is not genetically linked to ABCA1. In this category, two affected individuals were tested from NL-008, while four affected individuals were tested from NL-001. The remaining six individuals with a low HDL phenotype are not related to one another, and were chosen from distinct pedigrees. Of those individuals with high HDL, seven of them were unrelated to one another. It is not yet clear if the high HDL observed in these individuals has a clear genetic basis in family members. The remaining 14 individuals with a high HDL phenotype, six of them are from family HA-1 and eight are from a distinct family, HA-3. Unaffected individuals related to those with both low and high HDL were also tested.
  • fatty acid esters were determined as follows. Cells from patient samples were washed twice with cold phosphate-buffered saline and total cellular lipids were extracted three times with CHCI3/MeOH (2:1 v/v). The three lipid extractions were combined in a screw-capped glass tube, dried under N2 gas at 40 °C in a heat block, and resuspended in toluene. Fatty acid methyl esters were produced from BCl3/MeOH (Alltech, Deerfield IL), extracted with hexane, dried, and resuspended in hexane.
  • BCl3/MeOH Alltech, Deerfield IL
  • Fatty acid methyl esters were identified using a Hewlett-Packard 6890 gas chromatograph equipped with a 7683 auto injector and an HP-5 column (30 m ' 0.25 mm, 0.25 ⁇ m film thickness) connected to a flame ionization detector set at 275 °C.
  • the injector was maintained at 250 °C.
  • the column temperature was held at 180 °C for 2 min following injection, increased to 200 °C at 8 °C/min, held at 200 °C for 15 min, and then increased to 250 °C at 8 °C/min.
  • the sample was stratified based on HDL levels to determine if the relationship between SCD activity (as measured by the 18:1/18:0 ratio) and TG levels was independent of the primary cause of the observed dyslipidemia.
  • Examples 1 and 2 establish for the first time a positive correlation between SCD1 activity and TG levels in mammals, as well as an inverse correlation between SCD1 activity and HDL in humans.
  • Our analysis of the asebia and SCD1 KO are definitive in their implication of SCD1 as the major contributor to the desaturation index. We have used this index as a surrogate for SCD1 activity in our human studies.
  • inhibitors of SCD1 function in mammals, including humans, are likely to both lower TG and raise HDL.
  • FCHL FCHL.
  • hyperiipidemic strain hyperiipidemic strain
  • the hyperiipidemic mouse HcB-19 showed an elevated 18:1/18:0 desaturation index.
  • This mouse model of familial combined hyperlipidemia displays elevated levels of TG, cholesterol, as well as increased secretion of VLDL and apoB (Castellani et al, Mapping a gene for combined hyperlipidaemia in a mutant mouse strain. Nat Genet ;18(4):374-7 (1998).
  • Plasma fatty acid analysis demonstrated that these animals have a significantly elevated 18:1/18:0 ratio when compared to unaffected controls of the parental strain (Figure 13).
  • the HcB-19 animals did not, however, show a significant elevation of the 16:1/16:0 index when compared to controls. Therefore, we observe a positive correlation between the 18:1/18:0 desaturation index and TG levels in this animal model of FCHL.
  • This example reports, for the first time, the complete genomic promoter sequence of human SCDL This promoter is used herein to identify regulatory elements that modulate and control SCD1 expression in humans, and identifies regulatory proteins that are suitable targets for small molecule intervention to modulate expression of SCD1 in humans.
  • the human SCD1 promoter sequence is set forth at SEQ ID No. 1. This sequence has not been accurately annotated in Genbank and has been reported as 5'UTR in a number of records.
  • Figure 14 illustrates the location of regulatory sequences and binding sites in the homologous region of the mouse SCD1 and human SCD1 promoter and 5'-flanking regions.
  • the top scale denotes the position relative to the transcriptional start site. Important promoter sequence elements are indicated.
  • the human SCD1 promoter structure is similar to that of the mouse SCD1 isoform and contains conserved regulatory sequences for the binding of several transcription factors, including the sterol regulatory element binding protein (SREBP), CCAAT enhancer binding protein-alpha (C/EBPa) and nuclear factor-1 (NF-1) that have been shown to transactivate the transcription of the mouse SCD gene.
  • SREBP sterol regulatory element binding protein
  • C/EBPa CCAAT enhancer binding protein-alpha
  • NF-1 nuclear factor-1
  • a human placenta genomic library in bacteria-phage I EMBL3 was screened with a 2.0 kb Pstl insert of the mouse pC3 cDNA (Ntambi, J. M.,
  • Human stearoyl- CoA desaturase alternative transcripts generated from a single gene by usage of tandem polyadenylation sites. Biochem. J. 340: 255-264) was synthesized and used to sequence the two phage clones by the dideoxy nucleotide chain termination method. A preliminary sequence was generated and primers upstream
  • primers were designed to amplify approximately 540 bases of the promoter region upstream of the transcription start site: These primers contain inserted restriction enzyme sites (underlined), Kpn1 for upstream, and Bglll for downstream, with a 4 base overhang region to allow restriction enzyme digestion. PCR was then performed on the phage clones and the amplified 500bp fragment was isolated from a 1% agarose gel.
  • the amplified fragment was digested with Kpn1 and Bglll and then cloned into the Kpn1 and Bglll sites of the pGL3 basic vector (Promega) that contains the luciferase reporter gene and transformed into DH5 competent
  • Plasmid DNA was purified on Qiagen columns and sequenced by the dideoxynucleotide chain termination method using as primers corresponding to DNA sequences within the multiple cloning site but flanking the inserted DNA.
  • the SCD promoter luciferase gene construct that was generated was designated as pSCD-500.
  • RNA-Tota ⁇ RNA was isolated from HepG2 cells using the acid guanidinium-phenol-chloroform extraction method. Twenty micrograms of total RNA was separated by 0.8% agarose/2.2 M formaldehyde gel electrophoresis and transferred onto nylon membrane. The membrane was hybridized with 32 P-labeled human SCD cDNA probe generated by PCR as follows: pAL15 probe was used as control for equal loading.
  • Immunoblotting- Cell extracts were prepared from HepG2 cells that had been treated with the various fatty acids or cholesterol as described by Heinemann et al (17). The same amount of protein (60 ⁇ g) from each fraction was subjected to 10% SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P transfer membranes at 4 °C. After blocking with 10% non-fat milk in TBS buffer (pH 8.0) plus 0.5% Tween at 4 °C overnight, the membrane was washed and incubated with rabbit anti-rat SCD as primary antibody (17) and goat anti- rabbit IgG-HRP conjugate as the secondary antibody. Visualization of the SCD protein was performed with ECL western blot detection kit.
  • Cell Culture and DNA transfections - HepG2 cells were grown in Low Glucose DMEM supplemented with 10% Fetal Bovine Serum and 1% Penicillin/Streptomycin solution and maintained at 37 C, 5% C0 2 in a humidified incubator. Cells were passaged into 6 cm dishes to give 40-70% confluence in about 12-16 hours. Cells were then transfected with 5 ⁇ g plasmid DNA per plate of pSCD-500 or the Basic PGL3 reporter as well as well as the pRL-TK, internal controls (Promega) using the LT-1 transfection reagent (Pan Vera).
  • RESULTS The sequence of the amplified promoter region of the SCD1 gene is shown at SEQ ID. No. 1.
  • mice SCD1 promoter sequence When compared to the mouse SCD1 promoter sequence, it was found that several functional regulatory sequences identified in the mouse SCD1 promoter are absolutely conserved at the nucleotide level and also with respect to their spacing within the proximal promoters of the two genes (Fig 14). Both the TTAATA homology, the C/EBPa and NF-1 are in the same locations in both the mouse SCD1 and human promoters. Further upstream the sterol regulatory element (SRE) and the two CCAAT box motifs that are found in the polyunsaturated fatty acid responsive element (PUFA-RE) of the mouse SCD1 and SCD2 promoters. The spacing of these elements is conserved in the three promoters.
  • SRE sterol regulatory element
  • PUFA-RE polyunsaturated fatty acid responsive element
  • the human luciferase promoter construct was co- transfected in HepG2 cells together with an expression vector containing SREBPIa. After 72 h, extracts of the transfected cells were assayed for luciferase activity. Data were normalized to cell extract expressing the Renilla luciferase as an internal control. As shown in figure SREBP transactivates the promoter in a dose dependent manner giving rise to an increase up to 40-fold. This experiment shows that SREBP plays a role in regulating the human SCD gene.
  • SREBP mediates PUFA repression of the human SCD gene, SCD promoter activity would not diminish upon treatment the transfected cells with PUFA. However addition of AA, EPA or DHA continued to repress SCD promoter activity with only a slight attenuation (data not shown). Thus, SREBP maturation does not seem to exhibit the selectivity required to explain PUFA control of SCD gene transcription suggesting that PUFA may utilize a different protein in addition to the SREBP to repress human SCD gene transcription.
  • hSCDI is transcriptionally regulated by SREBP, NF-Y, C/EBPalpha, PUFA-RE and alternate proteins and transcription regulators.
  • SREBP SREBP
  • NF-Y NF-Y
  • C/EBPalpha C/EBPalpha
  • PUFA-RE alternate proteins and transcription regulators.
  • Each one of these proteins is therefore be an attractive drug screening target for identifying compounds which modulate SCD1 expression in a cell; and thereby being useful for treating the human diseases, disorders and conditions which are taught by the instant invention.
  • SCD1 knock-out mice SCD1 knock-out mice.
  • C16:1 was dramatically decreased in the tissues of SCD1 -/- mice whereas a dramatic decrease in C18:1 was noted only in liver where SCD1 alone and not SCD2 is normally expressed.
  • 18:1 was only slightly decreased.
  • the monounsaturated fatty acids levels of the brain and eyeball which do not express SCD1 were unchanged.
  • the liver and skin of the SCD-/- mice were deficient in cholesterol esters and triglycerides while the eyelid in addition was deficient in eyelid-specific wax esters of long chain monounsaturated fatty acids mainly C20:1.
  • the eyelid of the SCD-/- mice had higher levels of free cholesterol.
  • the SCD-/- mice exhibited cutaneous abnormalities with atrophic sebaceous gland and narrow eye fissure with atrophic meibomian glands which is similar to the dry eye syndrome in humans.
  • SCD -/- mice were healthy and fertile but they have cutaneous abnormalities. These abnormalities started around weaning age (3-4 weeks) with dry skin, fine epidermal scaling, and hair loss which became more severe with aging. In addition, the mice exhibited narrow eye fissures. Pathological examination of the skin and eyelids showed the wild-type mice had a prominent and well-differentiated sebaceous and meibomian glands (data not shown). On the other hand, skin and eyelid of SCD-/- appeared atrophic acinar cells in the sebaceous and meibomian glands (data not shown). No abnormalities were found in cornea and retina (data not shown).
  • Wax triester ((mg/g eyelid) 36.8 ⁇ 4.4 10.3 ⁇ 0.8
  • Fig 16B shows use of a different solvent according to Nicolaids et al (Nicolaides, N., and Santos, E. C. (1985).
  • These triesters as well as the diesters were decreased by 72% in the SCD-/- mice.
  • the eyelid of wax triester content decreased by 72% in the SCD-/- mice.
  • Oleate is one of the most abundant fatty acids in the diet,.
  • the cellular monounsaturated fatty acids used for cholesterol ester and triglyceride synthesis could be synthesized either de novo by Fatty Acid Synthase and
  • cholesterol ester, wax ester and triglyceride levels in the eyelids of SCD -/- mice fed with high 18:1 n-9 were still lower than those of SCD +/+ mice (data not shown), suggesting that endogenously synthesized monounsaturated fatty acids are required for the synthesis of the cholesterol esters triglycerides and wax esters of mebum.
  • SCD -/- mice Similar to asebia mice which have a spontaneous mutation of SCD1, SCD -/- mice exhibited abnormalities of hair growth, skin, and eye with complete penetrance. These phenotypes were noticeable from weaning age.
  • Enser.M The role of insulin in the regulation of stearic acid desaturase activity in liver and adipose tissue from obese-hyperglycaemic (ob/ob) and lean mice. Biochem. J. 180, 551-558 (1979).
  • Enser.M Desaturation of stearic acid by liver and adipose tissue from obese- hypergiycaemic mice (ob/ob). Biochem. J. 148, 551-555 (1975).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)

Abstract

L'invention concerne l'utilisation de méthodes de criblage basées sur le rôle de la stéaroyl-CoA désaturase-1 ('hSCD1') humaine dans les maladies, troubles ou pathologies humains liés aux niveaux sériques de triglycérides, de particules VLDL, HDL et LDL et de cholestérol total ou à la production de sécrétions par les muqueuses, aux acides gras monoinsaturés, aux esters de cire et analogues. L'invention concerne également des conventions utilisées dans la prévention et/ou le traitement desdites maladies.
PCT/US2001/005855 2000-02-24 2001-02-23 Methodes et compositions utilisant la stearoyl-coa desaturase pour identifier des agents therapeutiques reduisant les triglycerides WO2001062954A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE01920143T DE01920143T9 (de) 2000-02-24 2001-02-23 Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
CA2398940A CA2398940C (fr) 2000-02-24 2001-02-23 Methodes et compositions utilisant la stearoyl-coa desaturase pour identifier des agents therapeutiques reduisant les triglycerides
JP2001561763A JP2003533978A (ja) 2000-02-24 2001-02-23 トリグリセリド減少治療薬を同定するステアロイルＣｏＡデサチュラーゼを使用する方法と組成物
AU2001247228A AU2001247228B2 (en) 2000-02-24 2001-02-23 Stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
DE60142692T DE60142692D1 (de) 2000-02-24 2001-02-23 Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
AT01920143T ATE475718T1 (de) 2000-02-24 2001-02-23 Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
AU4722801A AU4722801A (en) 2000-02-24 2001-02-23 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
EP01920143A EP1315831B8 (fr) 2000-02-24 2001-02-23 Methodes et compositions utilisant la stearoyl-coa desaturase pour identifier des agents therapeutiques reduisant les triglycerides
AU2007201711A AU2007201711B2 (en) 2000-02-24 2007-04-18 Methods and Compositions Using Stearoyl-CoA Desaturase to Identify Triglyceride Reducing Therapeutic Agents
AU2010200879A AU2010200879B2 (en) 2000-02-24 2010-03-09 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18452600P 2000-02-24 2000-02-24
US60/184,526 2000-02-24
US22169700P 2000-07-31 2000-07-31
US60/221,697 2000-07-31
US25577100P 2000-12-15 2000-12-15
US60/255,771 2000-12-15

Publications (3)

Publication Number Publication Date
WO2001062954A2 true WO2001062954A2 (fr) 2001-08-30
WO2001062954A8 WO2001062954A8 (fr) 2002-02-14
WO2001062954A3 WO2001062954A3 (fr) 2003-03-27

Family

ID=27391846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005855 WO2001062954A2 (fr) 2000-02-24 2001-02-23 Methodes et compositions utilisant la stearoyl-coa desaturase pour identifier des agents therapeutiques reduisant les triglycerides

Country Status (9)

Country Link
US (5) US6987001B2 (fr)
EP (2) EP1315831B8 (fr)
JP (2) JP2003533978A (fr)
AT (1) ATE475718T1 (fr)
AU (4) AU4722801A (fr)
CA (1) CA2398940C (fr)
DE (2) DE01920143T9 (fr)
PT (1) PT1315831E (fr)
WO (1) WO2001062954A2 (fr)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026944A2 (fr) * 2000-09-26 2002-04-04 Xenon Genetics, Inc. Techniques et compositions utilisant une nouvelle stearyle-coa desaturase hscd5
WO2002036780A2 (fr) * 2000-10-31 2002-05-10 Johnson & Johnson Consumer Companies, Inc. Promoteur du gene de stearoyl-coa desaturase
WO2003004692A2 (fr) * 2001-07-03 2003-01-16 Xenon Genetics, Inc. Procedes de criblage d'agents modulant les taux de cholesterol
WO2003070885A2 (fr) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Inhibition mediee de l'interference d'arn de l'expression du gene de la stearoyl-coa desaturase (scd) au moyen d'acides nucleiques d'interference courts
WO2003074662A2 (fr) * 2002-03-01 2003-09-12 Exelixis, Inc. Enzymes scd utilisees comme modificateurs de la voie p53 et procedes d'utilisation correspondants
WO2003075925A1 (fr) * 2002-03-08 2003-09-18 Wisconsin Alumni Research Foundation Procedes permettant de reduire la graisse l'adiposite et d'accroitre la masse corporelle maigre en reduisant l'activite de la stearyl-coa desaturase 1
WO2004010927A2 (fr) * 2002-07-25 2004-02-05 Wisconsin Alumni Research Foundation Methode d'accroissement de la sensibilite a l'insuline, de traitement et de prevention de diabetes de type 2
EP1429784A2 (fr) * 2001-08-29 2004-06-23 Xenon Genetics, Inc. Essais de criblage a haut rendement mettant en oeuvre des enzymes synthetiques d'acide gras
EP1431399A1 (fr) * 2002-12-20 2004-06-23 Clinigenetics Méthodes et composition permettant l'identification d'agents thérapeutiques des lésions liées aux plaques d'atherosclérose
WO2005011656A2 (fr) 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
WO2005011655A2 (fr) 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
WO2005011657A3 (fr) * 2003-07-30 2005-03-24 Xenon Pharmaceuticals Inc Derives de piperazine et utilisation comme agents therapeutiques
WO2005011653A3 (fr) * 2003-07-30 2005-04-14 Xenon Pharmaceuticals Inc Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
WO2005011654A3 (fr) * 2003-07-29 2005-04-14 Xenon Pharmaceuticals Inc Derives de pyridyle et utilisation de ceux-ci en tant qu'agents therapeutiques
WO2006014168A1 (fr) * 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Dérivés de nicotinamide et utilisation de ceux-ci comme agents thérapeutiques
WO2006034312A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques bicycliques et leur utilisation comme inhibiteurs de stearoyl-coa desaturase (scd)
WO2006034279A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
WO2006034338A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant que modulateurs de stearoyle-coa desaturase
WO2006034440A2 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
EP1648910A2 (fr) * 2003-07-15 2006-04-26 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression de la stearoyl-coa desaturase
WO2006086447A2 (fr) 2005-02-09 2006-08-17 Xenon Pharmaceuticals Inc. Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
WO2006101521A2 (fr) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
WO2007046868A2 (fr) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques
WO2007143597A2 (fr) 2006-06-05 2007-12-13 Novartis Ag Composés organiques
WO2008024390A2 (fr) 2006-08-24 2008-02-28 Novartis Ag Composés organiques
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
WO2009060053A1 (fr) 2007-11-09 2009-05-14 Smithkline Beecham Corporation Dérivés de 1,2,3-triazole destinés à être utilisés comme inhibiteurs de la stéaroyl-coa désaturase
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2010112520A1 (fr) 2009-04-01 2010-10-07 Novartis Ag Dérivés spiro pour la modulation de la stéaroyl-coa désaturase
US7816075B2 (en) 2000-02-24 2010-10-19 Xenon Pharmaceuticals Inc. Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7842696B2 (en) 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
EP2266566A2 (fr) 2001-06-07 2010-12-29 Xenon Pharmaceuticals Inc. Dérivés de nicotinamide et utilisation de ceux-ci comme agents thérapeutiques
WO2011030312A1 (fr) 2009-09-10 2011-03-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux inhibiteurs de stearoyl-coa-desaturase-1 et leurs utilisations
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
WO2011039358A1 (fr) 2009-10-01 2011-04-07 Novartis Ag Dérivés de pyrazole qui modulent la stéaroyl-coa désaturase
EP2316457A1 (fr) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Dérivés de pyridazine destinés à l'inhibition de la stearoyl-coa-desaturase humaine
US8039463B2 (en) 2008-03-20 2011-10-18 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8129376B2 (en) 2008-03-20 2012-03-06 Sundaresan Kumar Piperidine derivatives as inhibitors of stearoyl-CoA desaturase
US8153635B2 (en) 2007-09-20 2012-04-10 Irm Llc Compounds and compositions as modulators of GPR119 activity
US8293768B2 (en) 2006-08-15 2012-10-23 Novartis Ag Organic compounds
EP2540296A1 (fr) 2005-06-03 2013-01-02 Xenon Pharmaceuticals Inc. Dérivés d'arminothiazole utilisés comme inhibiteurs de la stéaroyl-coa désaturase humaine
US9187426B2 (en) 2008-06-27 2015-11-17 Novartis Ag Organic compounds

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579974B1 (en) * 1998-06-23 2003-06-17 The Regents Of The University Of California Acyl CoA:cholesterol acyltransferase (ACAT-2)
CA2429455A1 (fr) * 2000-11-17 2002-05-23 Xenon Genetics Inc. Genes a regulation lipidique, utilisations de ces genes et composes permettant leur modulation
US20050256068A1 (en) * 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7285395B2 (en) * 2004-06-09 2007-10-23 Wisconsin Alumni Research Foundation Stearoyl-CoA desaturase 4 gene
US20060281071A1 (en) * 2005-06-08 2006-12-14 Ntambi James M Stearoyl-CoA desaturase assay
US20070231335A1 (en) * 2005-07-20 2007-10-04 Bruce Beutler Compositions and methods for treating Gram positive bacterial infection in a mammalian subject
US20080182249A1 (en) * 2006-09-01 2008-07-31 Fox Brian G Expression systems for mammalian and mycobacterial desaturases
EP1932921A1 (fr) * 2006-12-13 2008-06-18 Novartis AG Procédé de criblage différentiel à base mutante simple pour des composés modulant une cible spécifique
US8153392B2 (en) * 2007-05-10 2012-04-10 Undurti N Das Method(s) of preventing, arresting, reversing and treatment of atherosclerosis
EP2161580A1 (fr) * 2008-09-02 2010-03-10 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Biomarqueurs pour identifier des sujets prédisposé à développer une résistance à l'insuline et pour déterminer l'état de résistance à l'insuline
US20110184027A1 (en) * 2008-09-25 2011-07-28 Glenmark Pharmaceuticals S.A. Tissue selective stearoyl-coa desaturase 1 inhibitors and cell based screening assay for their identification
US20100160323A1 (en) * 2008-12-23 2010-06-24 Alexander Bischoff NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
WO2011163560A1 (fr) * 2010-06-25 2011-12-29 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Méthodes de traitement utilisant l'acide sterculique
KR20140084164A (ko) * 2011-10-15 2014-07-04 제넨테크, 인크. 암의 치료를 위한 scd1 길항제
DE102014005771A1 (de) 2014-04-23 2015-10-29 Clariant International Ltd. Verwendung von wässrigen driftreduzierenden Zusammensetzungen
EP3529245A4 (fr) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. Composés et utilisations de ces derniers
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
CA3083000A1 (fr) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Composes et utilisations de ces composes
BR112021014583A2 (pt) 2019-01-24 2021-10-05 Yumanity Therapeutics, Inc. Compostos e utilizações dos mesmos
WO2023023227A1 (fr) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Procédés de traitement de la drépanocytose ou de la bêta thalassémie en utilisant des inhibiteurs du trajet alternatif du complément
WO2023023220A1 (fr) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la drépanocytose ou de la bêta-thalassémie à l'aide d'un inhibiteur de la voie alterne du complément

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3274330D1 (en) * 1982-08-02 1987-01-08 Unitika Ltd An intravenous nutrient
IN164555B (fr) 1986-02-14 1989-04-08 Adly Habib Nagy
JP3070611B2 (ja) * 1989-03-07 2000-07-31 サントリー株式会社 △▲上５▼―不飽和化酵素阻害剤
US5162179A (en) 1990-04-17 1992-11-10 Armstrong World Industries, Inc. Electrographic structure and process
EP0537178B2 (fr) 1990-05-25 2007-06-13 E.I. Du Pont De Nemours And Company Sequence nucleotidique de gene de desaturase de stearoyle-acp de soja
US5336974A (en) * 1991-12-23 1994-08-09 U.S. Philips Corporation High-pressure discharge lamp
US5554646A (en) * 1992-04-29 1996-09-10 Wisconsin Alumni Research Foundation Method for reducing body fat in animals
US5861485A (en) * 1994-08-23 1999-01-19 Millennium Pharmaceuticals, Inc. Polypeptides involved in body weight disorders, including obesity
US6162455A (en) 1997-01-22 2000-12-19 American Cyanamid Company Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals
CA2307941C (fr) * 1997-06-23 2008-09-09 Cornell Research Foundation, Inc. Procede d'alteration de composants nutritionnels du lait d'un animal en lactation
EP1100511A2 (fr) 1998-06-08 2001-05-23 Sambasiva R. Chavali Inhibition de l'activite de delta-9-desaturase au moyen de saponines
AU5774699A (en) 1998-08-14 2000-03-06 Johnson & Johnson Consumer Companies, Inc. Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
US20030064950A1 (en) 2001-02-23 2003-04-03 Ntambi James M. Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity
JP2003533978A (ja) * 2000-02-24 2003-11-18 ゼノン ジェネティクス，インコーポレイテッド トリグリセリド減少治療薬を同定するステアロイルＣｏＡデサチュラーゼを使用する方法と組成物
AU2006326815A1 (en) * 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
TW200826936A (en) * 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996 WATERS & NTAMBI: "Polyunsaturated fatty acids inhibit hepatic stearoyl-CoA desaturase-1 gene in diabetic mice." Database accession no. PREV199698795704 XP002209768 & LIPIDS, vol. 31, no. SUPPL., 1996, pages S33-S36, ISSN: 0024-4201 *
KUREBAYASHI S ET AL: "THIAZOLIDINEDIONES DOWNREGULATE STEAROYL-COA DESATURASE 1 GENE EXPRESSION IN 3T3-L1 ADIPOCYTES" DIABETES, NEW YORK, NY, US, vol. 46, December 1997 (1997-12), pages 2115-2118, XP002924128 ISSN: 0012-1797 *
NTAMBI: "Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol" J. LIPID RES., vol. 40, 1999, pages 1549-1558, XP001097612 *
PARK ET AL.: "Lipid level and type alter stearoyl CoA desaturase mRNA abundance differently in mice with distinct susceptibilities to diet-influenced diseases" J. NUTR., vol. 127, 1997, pages 566-573, XP002209767 *
See also references of EP1315831A2 *
SESSLER ET AL.: "Regulation of stearoyl-CoA desaturase 1 mRNA stability by polyunsaturated fatty acids in 3T3-L1 adipocytes" J. BIOL. CHEM., vol. 271, no. 47, 22 November 1996 (1996-11-22), pages 29854-29858, XP001094092 *
SINGH & NTAMBI: "Nuclear factor 1 is essential fir the expression of stearoyl-CoA desaturase 1 gene during preadipocyte differentiation" BIOCHIM. BIOPHYS. ACTA, vol. 1398, 1998, pages 148-156, XP002209766 *
WATERS ET AL.: "Localization of a negative thyroid hormone-response region in hepatic stearoyl-CoA desaturase gene 1" BIOCHEM. BIOPHYS RES. COMM., vol. 233, 1997, pages 838-843, XP002209765 *
ZHANG ET AL.: "Human stearoyl-CoA desaturase: alternative transcripts generated from a single gene by usage of tandem polyadenylation sites" BIOCHEM. J., vol. 340, 1999, pages 255-264, XP000910887 *

Cited By (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816075B2 (en) 2000-02-24 2010-10-19 Xenon Pharmaceuticals Inc. Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
WO2002026944A2 (fr) * 2000-09-26 2002-04-04 Xenon Genetics, Inc. Techniques et compositions utilisant une nouvelle stearyle-coa desaturase hscd5
WO2002026944A3 (fr) * 2000-09-26 2002-10-03 Xenon Genetics Inc Techniques et compositions utilisant une nouvelle stearyle-coa desaturase hscd5
US7232662B2 (en) 2000-09-26 2007-06-19 Xenon Pharmaceuticals Inc. Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5
WO2002036780A2 (fr) * 2000-10-31 2002-05-10 Johnson & Johnson Consumer Companies, Inc. Promoteur du gene de stearoyl-coa desaturase
WO2002036780A3 (fr) * 2000-10-31 2003-05-22 Johnson & Johnson Consumer Promoteur du gene de stearoyl-coa desaturase
EP2266566A2 (fr) 2001-06-07 2010-12-29 Xenon Pharmaceuticals Inc. Dérivés de nicotinamide et utilisation de ceux-ci comme agents thérapeutiques
EP2266566A3 (fr) * 2001-06-07 2011-01-12 Xenon Pharmaceuticals Inc. Dérivés de nicotinamide et utilisation de ceux-ci comme agents thérapeutiques
WO2003004692A2 (fr) * 2001-07-03 2003-01-16 Xenon Genetics, Inc. Procedes de criblage d'agents modulant les taux de cholesterol
WO2003004692A3 (fr) * 2001-07-03 2003-09-18 Xenon Genetics Inc Procedes de criblage d'agents modulant les taux de cholesterol
US7960358B2 (en) 2001-07-30 2011-06-14 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US7294480B2 (en) 2001-08-29 2007-11-13 Xenon Pharmaceuticals Inc. High throughput screening assays using fatty acid synthetic enzymes
US6759208B2 (en) 2001-08-29 2004-07-06 Xenon Genetics Inc. High throughput screening assays using fatty acid synthetic enzymes
EP1429784A2 (fr) * 2001-08-29 2004-06-23 Xenon Genetics, Inc. Essais de criblage a haut rendement mettant en oeuvre des enzymes synthetiques d'acide gras
EP1429784A4 (fr) * 2001-08-29 2005-09-14 Xenon Genetics Inc Essais de criblage a haut rendement mettant en oeuvre des enzymes synthetiques d'acide gras
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
WO2003070885A2 (fr) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Inhibition mediee de l'interference d'arn de l'expression du gene de la stearoyl-coa desaturase (scd) au moyen d'acides nucleiques d'interference courts
WO2003070885A3 (fr) * 2002-02-20 2004-11-11 Sirna Therapeutics Inc Inhibition mediee de l'interference d'arn de l'expression du gene de la stearoyl-coa desaturase (scd) au moyen d'acides nucleiques d'interference courts
WO2003074662A3 (fr) * 2002-03-01 2004-11-25 Exelixis Inc Enzymes scd utilisees comme modificateurs de la voie p53 et procedes d'utilisation correspondants
US8771942B2 (en) * 2002-03-01 2014-07-08 Exelixis, Inc. SCDs as modifiers of the p53 pathway and methods of use
US20100159470A1 (en) * 2002-03-01 2010-06-24 Exelixis, Inc. SCDs As Modifiers of the p53 Pathway and Methods of Use
WO2003074662A2 (fr) * 2002-03-01 2003-09-12 Exelixis, Inc. Enzymes scd utilisees comme modificateurs de la voie p53 et procedes d'utilisation correspondants
WO2003075925A1 (fr) * 2002-03-08 2003-09-18 Wisconsin Alumni Research Foundation Procedes permettant de reduire la graisse l'adiposite et d'accroitre la masse corporelle maigre en reduisant l'activite de la stearyl-coa desaturase 1
WO2004010927A2 (fr) * 2002-07-25 2004-02-05 Wisconsin Alumni Research Foundation Methode d'accroissement de la sensibilite a l'insuline, de traitement et de prevention de diabetes de type 2
WO2004010927A3 (fr) * 2002-07-25 2004-07-15 Wisconsin Alumni Res Found Methode d'accroissement de la sensibilite a l'insuline, de traitement et de prevention de diabetes de type 2
JP2006510379A (ja) * 2002-12-20 2006-03-30 クリニジェネティクス アテローム硬化性プラーク病変の治療剤を同定するための方法ならびに組成物
WO2004057031A3 (fr) * 2002-12-20 2004-08-12 Clinigenetics Procedes et composition permettant d'identifier des agents therapeutiques pouvant soigner des lesions provoquees par des plaques d'atherosclerose
WO2004057031A2 (fr) * 2002-12-20 2004-07-08 Clinigenetics Procedes et composition permettant d'identifier des agents therapeutiques pouvant soigner des lesions provoquees par des plaques d'atherosclerose
EP1431399A1 (fr) * 2002-12-20 2004-06-23 Clinigenetics Méthodes et composition permettant l'identification d'agents thérapeutiques des lésions liées aux plaques d'atherosclérose
EP1648910A2 (fr) * 2003-07-15 2006-04-26 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression de la stearoyl-coa desaturase
EP1648910A4 (fr) * 2003-07-15 2008-02-27 Isis Pharmaceuticals Inc Modulation antisens de l'expression de la stearoyl-coa desaturase
WO2005011654A3 (fr) * 2003-07-29 2005-04-14 Xenon Pharmaceuticals Inc Derives de pyridyle et utilisation de ceux-ci en tant qu'agents therapeutiques
JP4884219B2 (ja) * 2003-07-29 2012-02-29 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリジル誘導体および治療剤としてのその用途
US8383628B2 (en) 2003-07-29 2013-02-26 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
US7763618B2 (en) 2003-07-29 2010-07-27 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
JP2007500716A (ja) * 2003-07-29 2007-01-18 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリジル誘導体および治療剤としてのその用途
US7514436B2 (en) 2003-07-30 2009-04-07 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7456180B2 (en) 2003-07-30 2008-11-25 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
EP3042895A1 (fr) 2003-07-30 2016-07-13 Xenon Pharmaceuticals Inc. Dérivés de la pipérazine et leur utilisation en tant qu'agents thérapeutiques
WO2005011656A2 (fr) 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
WO2005011655A2 (fr) 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
US8148378B2 (en) 2003-07-30 2012-04-03 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as inhibitors of stearoyl-CoA desaturase-1 activity in a mammal
US7335658B2 (en) 2003-07-30 2008-02-26 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2005011657A3 (fr) * 2003-07-30 2005-03-24 Xenon Pharmaceuticals Inc Derives de piperazine et utilisation comme agents therapeutiques
US8030488B2 (en) 2003-07-30 2011-10-04 Xenon Pharmaceuticals Inc. Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agents
WO2005011655A3 (fr) * 2003-07-30 2005-03-24 Xenon Pharmaceuticals Inc Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
EP2316825A1 (fr) 2003-07-30 2011-05-04 Xenon Pharmaceuticals Inc. Dérivés de pyridyle et utilisation de ceux-ci en tant qu'agents thérapeutiques
WO2005011656A3 (fr) * 2003-07-30 2005-05-06 Xenon Pharmaceuticals Inc Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
EP2316828A1 (fr) 2003-07-30 2011-05-04 Xenon Pharmaceuticals Inc. Dérivés de piperazine et leurs utilisations en tant qu'agents thérapeutiques
EP2316827A1 (fr) 2003-07-30 2011-05-04 Xenon Pharmaceuticals Inc. Dérivés de pipérazine et leurs utilisations en tant qu'agents thérapeutiques
EP2316826A1 (fr) 2003-07-30 2011-05-04 Xenon Pharmaceuticals Inc. Dérivés de pyridazine et utilisation de ceux-ci en tant qu'agents thérapeutiques
US7605161B2 (en) 2003-07-30 2009-10-20 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
KR100934554B1 (ko) 2003-07-30 2009-12-29 제논 파마슈티칼스 인크. 피리다진 유도체 및 그의 치료제로서의 용도
WO2005011653A3 (fr) * 2003-07-30 2005-04-14 Xenon Pharmaceuticals Inc Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2006014168A1 (fr) * 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Dérivés de nicotinamide et utilisation de ceux-ci comme agents thérapeutiques
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
WO2006034338A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant que modulateurs de stearoyle-coa desaturase
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
EP2266569A2 (fr) 2004-09-20 2010-12-29 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
WO2006034312A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques bicycliques et leur utilisation comme inhibiteurs de stearoyl-coa desaturase (scd)
EP2269610A2 (fr) 2004-09-20 2011-01-05 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
WO2006034279A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
JP2008513496A (ja) * 2004-09-20 2008-05-01 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
WO2006101521A2 (fr) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
EP2316457A1 (fr) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Dérivés de pyridazine destinés à l'inhibition de la stearoyl-coa-desaturase humaine
US7547698B2 (en) 2004-09-20 2009-06-16 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)
WO2006034440A2 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2316458A1 (fr) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Derives de pyridazine destines a l'inhibition du desaturase-coa-stearoyl de l'humain
WO2006086447A3 (fr) * 2005-02-09 2007-04-05 Xenon Pharmaceuticals Inc Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
WO2006086447A2 (fr) 2005-02-09 2006-08-17 Xenon Pharmaceuticals Inc. Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
WO2007046868A2 (fr) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques
WO2007046868A3 (fr) * 2005-05-19 2007-07-12 Xenon Pharmaceuticals Inc Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques
EP2540296A1 (fr) 2005-06-03 2013-01-02 Xenon Pharmaceuticals Inc. Dérivés d'arminothiazole utilisés comme inhibiteurs de la stéaroyl-coa désaturase humaine
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
WO2007143597A2 (fr) 2006-06-05 2007-12-13 Novartis Ag Composés organiques
US8293768B2 (en) 2006-08-15 2012-10-23 Novartis Ag Organic compounds
WO2008024390A2 (fr) 2006-08-24 2008-02-28 Novartis Ag Composés organiques
US7842696B2 (en) 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
US8258156B2 (en) 2007-09-20 2012-09-04 Irm Llc Compounds and compositions as modulators of GPR119 activity
US8153635B2 (en) 2007-09-20 2012-04-10 Irm Llc Compounds and compositions as modulators of GPR119 activity
EP2368887A1 (fr) 2007-11-09 2011-09-28 Glaxosmithkline LLC Dérivés de 1,2,3-triazole destinés à être utilisés comme inhibiteurs de la stéaroyl-COA désaturase
WO2009060053A1 (fr) 2007-11-09 2009-05-14 Smithkline Beecham Corporation Dérivés de 1,2,3-triazole destinés à être utilisés comme inhibiteurs de la stéaroyl-coa désaturase
US8486977B2 (en) 2007-11-09 2013-07-16 Glaxosmithkline Llc 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors
US9051281B2 (en) 2007-11-09 2015-06-09 Glaxosmithkline Llc Compounds
US8039463B2 (en) 2008-03-20 2011-10-18 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
US8129376B2 (en) 2008-03-20 2012-03-06 Sundaresan Kumar Piperidine derivatives as inhibitors of stearoyl-CoA desaturase
US9187426B2 (en) 2008-06-27 2015-11-17 Novartis Ag Organic compounds
WO2010112520A1 (fr) 2009-04-01 2010-10-07 Novartis Ag Dérivés spiro pour la modulation de la stéaroyl-coa désaturase
WO2011030312A1 (fr) 2009-09-10 2011-03-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux inhibiteurs de stearoyl-coa-desaturase-1 et leurs utilisations
WO2011039358A1 (fr) 2009-10-01 2011-04-07 Novartis Ag Dérivés de pyrazole qui modulent la stéaroyl-coa désaturase

Also Published As

Publication number Publication date
EP2172560A3 (fr) 2010-09-29
JP2008131939A (ja) 2008-06-12
DE60142692D1 (de) 2010-09-09
PT1315831E (pt) 2010-11-04
JP2003533978A (ja) 2003-11-18
EP1315831B1 (fr) 2010-07-28
AU2010200879A1 (en) 2010-04-01
US7696151B2 (en) 2010-04-13
ATE475718T1 (de) 2010-08-15
AU2007201711B2 (en) 2009-12-10
WO2001062954A8 (fr) 2002-02-14
DE01920143T1 (de) 2004-05-19
EP1315831A2 (fr) 2003-06-04
AU2001247228B2 (en) 2007-01-18
CA2398940A1 (fr) 2001-08-30
US7790408B1 (en) 2010-09-07
AU2007201711A1 (en) 2007-05-10
US20110060014A1 (en) 2011-03-10
WO2001062954A3 (fr) 2003-03-27
CA2398940C (fr) 2012-02-21
AU2010200879B2 (en) 2012-01-19
US20050256033A1 (en) 2005-11-17
US20030157552A1 (en) 2003-08-21
DE01920143T9 (de) 2005-04-28
US7816075B2 (en) 2010-10-19
EP1315831B8 (fr) 2010-09-01
US20050250160A1 (en) 2005-11-10
AU4722801A (en) 2001-09-03
US6987001B2 (en) 2006-01-17
EP2172560A2 (fr) 2010-04-07

Similar Documents

Publication Publication Date Title
US7816075B2 (en) Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
AU2001247228A1 (en) Stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
US20090221677A1 (en) Methods for Reducing Body Fat and Increasing Lean Body Mass by Reducing Stearoyl-COA Desaturase 1 Activity
US20120164154A1 (en) Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
US7435559B2 (en) Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5
Miyazaki et al. Targeted disruption of stearoyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid
Zhang et al. Aberrant hepatic expression of PPARγ2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis
Quinzii et al. Tissue-specific oxidative stress and loss of mitochondria in CoQ-deficient Pdss2 mutant mice
Natarajan et al. Signaling mechanisms of nuclear factor-κB-mediated activation of inflammatory genes by 13-hydroperoxyoctadecadienoic acid in cultured vascular smooth muscle cells
US20040209288A1 (en) Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis
Cimini et al. Presence and inducibility of peroxisomes in a human glioblastoma cell line
Gu et al. A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition
ES2349856T3 (es) Estearoil-coa desaturasa para identificar agentes terapéuticos que reducen los trigliceridos.
US7285395B2 (en) Stearoyl-CoA desaturase 4 gene
Okita Effect of peroxisome proliferators on microsomal P450 reactions
Kuefner The Role of Secretory Phospholipase A2 Group IIA in Obesity and Metabolism
Sinnokrak Nuclear receptor regulation of the UDP-glucuronosyltransferase 1 locus and the role of the pregnane X receptor as a tissue-specific master regulator
Mattijssen et al. Hypoxia inducible lipid droplet associated (HILPDA) is a novel PPAR target involved in hepatic triglyceride secretion
Vechoropoulos et al. Research Article The Proatherogenic Effect of Chronic Nitric Oxide Synthesis Inhibition in ApoE-Null Mice Is Dependent on the Presence of PPAR�

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 35/2001 UNDER "PUBLISHED", ADD "SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELYIN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU."

WWE Wipo information: entry into national phase

Ref document number: 2398940

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001920143

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 561763

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001247228

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001920143

Country of ref document: EP